1 Protocol Update #07 
XX/XX/2017 
 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
_________________________________________  
PROTOCOL UPDATE TO ALLIANCE A091101  
_________________________________________ 
 
CARBOPLATIN -PACLITAXEL INDUCTION CHEMOTHERAPY AND ABT -888  (VELIPARIB ) – A PHASE 
1/RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL 
CARCINOMA OF THE HEAD AND NECK 
NCI-supplied  agent(s): ABT -888 (Veliparib) (NSC #737664, IND#[ZIP_CODE]) 
     
X Update :   Status Change : 
     
 Eligibility changes    Activation  
     
X Therapy / Dose Modifications / Study Calendar changes    Closure  
     
 Informed Consent changes    Suspension / temporary closure  
     
 Scientific / Statistical Considerations changes    Reactivation  
     
 Data Submission /  Forms changes     
     
X Editorial / Administrative changes     
     
 Other :     
 
Expedited review is allowed. IRB (or disapproval) is required within [ADDRESS_1277769] guidelines.  
 
UPDATES TO THE PROTOCOL:  
CTSU Contact [CONTACT_910201] . 
 
Section 10.0 (Study Calendar)  
-Footnote “***” has been updated. The 3-month time point has been removed  from the first sentence. 
-An “X” has replaced the “C” in the Imaging row under the last column, Clinical Follow-up.  Footnote 
“C” has been removed because the timing was not correct. Imaging should be done per footnote “***”. 
Subsequent footno tes have been re-lettered .  
 
UPDATES TO THE MODEL CONSENT:  
No changes have been made to the model consent form.  
 
A replacement protocol and model consent document have been issued.  
____________________________________________________________ 
ATTACH TO THE FRONT OF EVERY COPY OF THIS PROTOCOL  
  ___________________________________________________________  
Alliance A091101  
 
Version Date: 08/11/2017  1 Update #07  ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
 
 
ALLIANCE A091101 
 
 
CARBOPLATIN -PACLITAXEL  INDUCTION CHEMOTHERAPY AND ABT -888  (VELIPARIB ) – A PHASE 
1/RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL 
CARCINOMA OF THE HEAD AND NECK 
 
NCI-supplied agent : ABT -888 (Veliparib) (NSC #737664, IND#[ZIP_CODE]) 
 
Clinical Trials.gov Identifier: [STUDY_ID_REMOVED] 
 
Study Chair 
Everett E. Vokes , M.D. 
John E. Ultmann [CONTACT_910243], Department of Medicine  
Physician -in-Chief, University of Chicago Medicine and Biological Sciences  
[ADDRESS_1277770], MC 6092 
Chicago, IL [ZIP_CODE] 
Tel: [PHONE_11238]  Fax: 773 -702-4427 
[EMAIL_10364]  
 
Community Oncologist Co -Chair  
Bruce Brockstein, M.D.  
Tel: 847 -570-2112 Fax: 847 -570-1041  
[EMAIL_17348]  
  
Committee Co-Chair  Committee Co -Chair  
Pamela Munster, M.D.  Gary K. Schwartz, M.D.  
Tel: 415 502 -3598 Fax: (415) 353 -7779  Tel: 212 -305-2055 Fax: 212 - 717-3085  
[EMAIL_9097]  [EMAIL_17349]  
 
 
Primary Statistician  Protocol Coordinator  
Nathan R. Foster, MS  Krista L. Garbacz  
Tel: (507) 284 -5051   Tel: 773 -702-9269 Fax: 312 -345-0117  
[EMAIL_9906]  [EMAIL_17350]  
 
 
Open to the following  NCTN institutions:  
Clev eland Clinic [LOCATION_012]  
Northshore University HealthSystem 
Northwestern University 
University of Chicago  
University of [LOCATION_005]  
University of North Carolina at Chapel Hill  
Washington University School of Medicine  
Allia nce A091101  
Version Date: 08/11/2017  2  Update #[ADDRESS_1277771] 
Chicago, IL  [ZIP_CODE] 
Tel: [PHONE_18898] Fax: [ADDRESS_1277772]. SW 
[COMPANY_002]ster MN [ZIP_CODE] 
 
Expedited Adverse Event Reporting  
https://eapps-ctep.nci.nih.gov/ctepaers Medidata Rave  iMedidata portal  
https://login.imedidata.com  
OPEN (Oncology Patient Enrollment Network)  
https://open.ctsu.org 
 
Protocol Resources:  
A091101 Data Manager 
Deborah Papenfus 
[PHONE_18899]  
[EMAIL_17351]  
A091101 Nursing Contact 
[CONTACT_910202]  
E-mail: nhannigan @bsd.uchicago.edu  A091101 Pharmacy Contact 
[CONTACT_910203], PharmD, BCOP 
[PHONE_18900] 
[EMAIL_17352]  
 
Alliance Biorepository at Ohio State University  (OSU)  
The Ohio State University  
Innovation Centre 
[ADDRESS_1277773] 
Columbus, OH [ZIP_CODE] 
Tel: [PHONE_16778]  Fax: [PHONE_16774] 
[EMAIL_15293]   
 
Protocol -related questions may be directed as follows:  
Questions  Contact (via email)  
Questions regarding patient eligibility, treatment, 
and dose modification:  Study Chair, Nursing Contact, Protocol 
Coordinator, or (where available) Data Manager  
Questions related to data submission, RAVE or 
patient follow -up: Data Manager  
Questions regarding the protocol document  and 
model informed consent : Protocol Coordinator  
Questions related to IRB review : regulatory@alliancenctn .org 
Questions regarding CTEP -AERS  reporting:  Regulatory Affairs Manager,  
[EMAIL_17353] , (773) 702 -9814  
 
Document History  Effective Date:    
Activation  October 22, 2012  Update #4  12/15/2015  
Update #1  08/05/2013  Update #05  07/01/2016  
Update #2  08/01/2014  Update #06  06/15 /2017  
Update #3  08/01 /2015  Update #0 7 XX/XX/2017  
Alliance A091101  
 
Version Date: 08/11/2017  3 Update #07  CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_910204] : For patient enrollments:  For study data  submission:  
Regulatory documentation must 
be submitted to the CTSU via 
the Regulatory Submission 
Portal.  
Regulatory Submission Portal: 
(Sign in at www.ctsu.org ,            
and select the Regulatory 
Submission sub-tab under the 
Regulatory tab.)  
 
Institutions with patients  
waiting that are unable to use 
the Portal should alert the CTSU Regulatory Office 
immediately at 1 -[PHONE_102] 
to receive further instruction 
and support. 
 
Contact  [CONTACT_311326] [PHONE_3811] 
for regulatory assistance.  Please refer to the patient 
enrollment section  of the protocol 
for instructions on using the 
Oncology Patient Enrollment 
Network (OPEN) which can be 
accessed at 
https://www.ctsu.org/OPEN_SYS
TEM/  or https://OPEN.cts u.org . 
 
Contact [CONTACT_280527] -related questions 
at [EMAIL_013] . 
  Data collection for this study 
will be done exclusively through 
Medidata Rave.  Please see the 
data submission section of the 
protocol for further instructions.  
 
The most current version of the study protocol and all supporting  documents  must be downloaded 
from the protocol- specific Web page of the CTSU Member Web site located at https://www.ctsu.org .  
Access to the CTSU members’ web site is managed through the Cancer Therapy and Evaluation Program 
- Identity and Access Management (CTEP -IAM) registration system  and requires user log on with 
CTEP -IAM username [CONTACT_2383]. Include this statement if applicable : Permission to view and 
download this protocol and its supporting documents is restricted and is based on person and site roster  
assignment housed in the CTSU RSS.   
 
For clinical questions (i.e. patient eligibility or treatment -related ) contact [CONTACT_1016] [INVESTIGATOR_910180] n 
For non-clinical questions (i.e. unrelated to patient eligibility, treatment, or clinical data 
submission) contact [CONTACT_56113] e- mail:  
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
correspondence will  be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at  https://www.ctsu.org . 
  
 
  
Alliance A091101  
 
Version Date: 08/11/2017  4 Update #07   
Carboplatin -Paclitaxel Induction chemotherapy and ABT- 888 (Veliparib) – a Phase 1/Randomized 
Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head 
and Neck  
 
Phase 1 
 
Patient Eligibility  Required Lab Values  
Eligibl e patients are newly diagnosed and treatment naïve:  leukocytes  ≥ 3,000/mm3 
- Stage IVa -b SCC other than OPC, OR  ANC  ≥ 1,500/ mm3 
- OPC HPV -negative, Stage IVa -b platelets  ≥ 100,000/ mm3 
Patients must have measurable disease ( see §3.1.2 ) total bilirubin  ≤ 1.5 Institutional upper limit  
ECOG performance status 0 -1  of normal (ULN)  
Age >18 years  SGOT(AST) or   
Must be able to swallow the drug  SGPT(ALT)  ≤ 2.[ADDRESS_1277774]  
Able to understand and sign a written informed consent  document  Creatinine clearance  ≥ 60 mL/min/1.[ADDRESS_1277775]*  No other investigational agents  
No active seizure or history of seizure  * As calculated by [CONTACT_3158] -Gault.  
No allergies to similar agents of ABT -888 ( see §3.1.10 ) 
No impairment of GI function ( see §3.1.11 ) 
No uncontrolled intercurrent illness ( see §3.1.12 ) 
No pregnant or nursing women ( see §3.1.13 ) 
No HIV -positive patients on combination antiretroviral therapy ( see §3.1.14 ) 
No patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent ( see §3.1.15 ) 
No patients with other malignancies in the past 2 years (except carcinoma of the cervix or basal or squamous cell carcinoma o f 
the skin or surgically treated early stage solid tumors)  
 
 
Phase 1 Schema  
  Induction   Concomitant  
Chemoradiotherapy  
     
  Carboplatin -Paclitaxel  + ABT -888 
(veliparib )  Concurrent accelerated RT and cisplatin  
(One 6 -week cycle) 
  (Two 3 -week cycles )  
R    Cisplatin  100 mg/m2 IV Days 1 and 22  
Radiotherapy  72 Gy over 6 weeks  E  Carboplatin  AUC 6 IV  on Day 1   
G  Paclitaxel  100 mg/m2 IV on Day s 1, 8, 15   
I     
S    OR 
T  PLUS ABT -888 (veliparib )   
E  p.o. b.i.d. Days 1-7 (dose based  on dose 
cohort)   TFHX  
 (Five 2 -week cycles)  R   
    Hydroxyurea  500 mg p.o. b.i.d., Days 1-5 
5-FU 600 mg/m2/day IV on Days 1-5 
Paclitaxel  100 mg/m2 IV on Day 1 
Radiotherapy 150 cGy b.i.d. on Days 1-5     
  See Section 5.1.1  for more information   
  on dose  cohorts   
     
Alliance A091101  
 
Version Date: 08/11/2017  5 Update #07  Carboplatin -Paclitaxel Induction chemotherapy and ABT- 888 (Veliparib) – a Phase 1/Randomized 
Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head 
and Neck  
 
Phase 2 
 
Patient Eligibility  Required Lab Values  
Eligible patients are treatment naïve and:  leukocytes  ≥ 3,000/mm3 
- Stage IVa -b SCC other than OPC, OR  ANC  ≥ 1,500/ mm3 
- OPC HPV -negative, Stage IVa -b, OR  platelets  ≥ 100,000/ mm3 
- OPC HPV positive with greater than 10pack -year total bilirubin  ≤ 1.5 Institutional upper limit  
smoking history and N2b -N3 disease   of normal (ULN)  
Patients must have measurable disease ( see §3.2.2 ) SGOT(AST) or   
ECOG performance status 0-1 SGPT(ALT)  ≤ 2.[ADDRESS_1277776]  
Age >[ADDRESS_1277777] be able to swallow the drug  
Able to understand and sign a written informed consent  Creatinine 
clearance  ≥ 60 mL/min/1.[ADDRESS_1277778] * 
document  * As calculated by [CONTACT_3158] -Gault.  
No other investigational agents  
No active seizure or history of seizure    
No allergies to similar agents of ABT -888 ( see §3.2.10 ) 
No impairment of GI function ( see §3.2.11 ) 
No uncontrolled intercurrent illness ( see §3.2.12 ) 
No pregnant or  nursing women ( see §3.2.13 ) 
No HIV -positive patients on combination antiretroviral therapy ( see §3.2.14 ) 
No patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent ( see §3.2.15 ) 
No patients with other malignancies in the past 2 years (except carcinoma of the cervix or basal or squamous cell carcinoma 
of the skin or surgically treated early stage solid tumors)  
Phase 2 Schema  
 
 
  
Induction   Concomitant  
Chemoradiotherapy  
  Two 3 -week cycles    
     
  Carboplatin  AUC 6  IV on Day 1  Concurrent accelerated RT and cisplatin  
(One 6 -week cycle)  
  Paclitaxel  100 mg/m2 IV on Day s 1, 8, 15    
R    Cisplatin  100 mg/m2 IV Days 1 and 22  
Radiotherapy  72 Gy over 6 weeks  A  ABT -888 (Veliparib)  (dose   
N  determined in phase I of study )  
D  b.i.d. on Days 1-7   
O    OR 
M     
I  Carboplatin  AUC 6  IV on Day 1  TFHX  
 (Five 2 -week cycles)  Z  Paclitaxel  100 mg/m2 IV on Day 1, 8, 15   
E    Hydroxyurea  500 mg p.o. b.i.d., Days 1-5 
5-FU 600 mg/m2/day IV on Days 1-5 
Paclitaxel  100 mg/m2 IV on Day 1 
Radiotherapy 150 cGy b.i.d. on Days 1-5   Placebo  b.i.d. on Days 1-7  
    
    
Alliance A091101  
 
Version Date: 08/11/2017  6 Update #07  TABLE OF CONTENTS  
 
SECTION                                                                                                              PAGE  
1.0 OBJECTIVES  ....................................................................................................................... 8  
1.1 Primary Objectives  ............................................................................................................................. 8 
1.2 Secondary Objectives (Phase II)  ........................................................................................................ 8 
2.0 BACKGROUND  ................................................................................................................... 8  
2.1 Locally Advanced Head and Neck Cancer (LAHNC)  ....................................................................... 8 
2.2 Patterns of Failure in LAHNC  ............................................................................................................ 9 
2.3 Induction Chemotherapy .................................................................................................................... 9 
2.4 Concurrent chemoradiotherapy ........................................................................................................ 10 
2.5 Risk Stratification in LAHNC  .......................................................................................................... 12 
2.6 ABT -888 (Veliparib) ......................................................................................................................... 14 
2.7 Rationale for Combination of ABT -888 and Induction Chemotherapy ............................................ 21 
2.8 Correlatives Studies Background ..................................................................................................... 21 
3.0 PATIENT SELECTION  ..................................................................................................... 23  
3.1 Eligibility Criteria for P hase 1 Component ...................................................................................... 23 
3.2 Eligibility Criteria for Phase 2 Component ...................................................................................... 24 
3.3 Inclusion of Women and Minorities ................................................................................................. 26 
4.0 REGISTRATION/RANDOMIZATION PROCEDURES AND STRATIFICATION  ...... 26  
4.1 Phase I Patient Registration  .............................................................................................................. 26 
4.2 Phase II Patient Registration  ............................................................................................................ 28 
4.3 Stratification Factors  ........................................................................................................................ 29 
5.0 TREATMENT PLAN  ......................................................................................................... 29  
5.1 Phase I .............................................................................................................................................. 29 
5.2 Phase II  ............................................................................................................................................. 42 
5.3 Concomitant Medication and Supportive Care Guidelines .............................................................. 44 
5.4 Duration of Therapy  ......................................................................................................................... 44 
5.5 Duration of Follow Up ..................................................................................................................... 44 
5.6 Criteria for Removal from Study ...................................................................................................... 45 
6.0 DOSE MODIFICATIONS FOR PHASE I ONLY  ............................................................. 46  
6.1 Dose Reduction and Delays during Induction .................................................................................. 46 
6.2 Dose Modifications during Chemoradiotherapy, Option 1 (cisplatin) for phase I ........................... 49 
6.3 Dose modifications during Chemoradiotherapy, Option 2 (hydroxyurea/5FU/paclitaxel) for phase 
I  .................................................................................................................................................... 50 
7.0 ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS  .............................. [ADDRESS_1277779] (CAEPR)  ............................................... 51 
7.2 Adverse Event Characteristics  .......................................................................................................... 55 
7.3 Expedited Adverse Event Reporting ................................................................................................ 55 
7.4 Routine Adverse Event Reporting .................................................................................................... 57 
8.0 PHARMACEUTICAL INFORMATION  ........................................................................... 58  
8.1 CTEP IND Agent ABT -888 (NSC 737664 ;  IND #[ZIP_CODE]; veliparib) .............................................. 58 
8.2 Commercial Agents  .......................................................................................................................... 61 
9.0 CORRELATIVE SCIENCE COMPANION STUDY ........................................................ 63  
10.0  STUDY CALENDAR  ......................................................................................................... 64  
Alliance A091101  
 
Version Date: 08/11/2017  7 Update #[ADDRESS_1277780]  ................................................................................................................ 67 
11.5  Formal statistical definitions  ....................................................................................................... 70 
12.0  DATA REPORTING / REGULATORY REQUIREMENTS  ............................................ 70  
12.1  Data Reporting  ............................................................................................................................ 70 
12.2  Collaborative Agreements Language .......................................................................................... 70 
13.0  STATISTICAL CONSIDERATIONS  ................................................................................ 72  
13.1  Study Design/Endpoints .............................................................................................................. 72 
13.2  Sample Size/Accrual Rate  ........................................................................................................... 73 
13.3  Stratification Factors  ................................................................................................................... 73 
13.4  Analysis of Secondary Endpoints ............................................................................................... 73 
13.5  Reporting and Exclusions ........................................................................................................... 74 
14.0  REFERENCES  .................................................................................................................... 75  
APPENDIX A- Performance Status Criteria  .............................................................................. 79  
APPENDIX B - Head & Neck Staging ......................................................................................... 80  
APPENDIX C - ABT -888 PATIENT MEDICATION CALENDAR  .......................................... 85  
 
  
Alliance A091101  
 
Version Date: 08/11/2017  8 Update #07  1.0 OBJECTIVES  
1.1 Primary Objectives  
1.1.1 Phase I  
Determine the maximum tolerated dose (MTD), recommended Phase II dose, dose limiting 
toxicity (DLT), and safety of ABT -888 (veliparib)  with carboplatin and paclitaxel  induction 
chemotherapy in locoregionally advanced head and neck (LAHNC) patients.  
1.1.2 Randomized Phase II  
Compare magnitude of tumor shrinkage (response) following 2 cycles of induction 
chemotherapy with and without ABT-888 in LAHNC. 
1.2 Secondary Objectives (Phase II)  
Compare progression- free (PFS), disease -specific (DSS), and overall survival (OS) in subjects 
treated with or without ABT-888. 
2.0 BACKGROUND  
2.1 Locally Advanced Head and Neck Cancer (LAHNC)  
The paradigm of combined chemoradiotherapy for LAHNC dates to the early 1990s. Several 
publications on randomized controlled trials of radiation alone versus radiation plus 
chemotherapy were then reported. The outcome of these trials varied, but several meta -analyses 
showed consistent increased response rates, increased disease control, and i mproved survival in 
the trials incorporating concurrent cisplatin- based chemoradiotherapy.1-5 When the analysis was 
restricted to concurrent cisplatin -based chemotherapy with radiation, an 8% absolute survival 
advantage at 5 years was observed. This benefi t corresponded to a 19% reduction in the risk of 
death. Notably, the meta- analysis data sets represent more than 16,[ADDRESS_1277781] long-term function which, in turn, is related to radiotherapy 
volumes. Despi[INVESTIGATOR_910181] -term toxicity in 
a substantial manner. Radiotherapy planning techniques, especially intensity modulated radiotherapy (IMRT), have the ability to spare normal structures from receiving full doses of 
radiotherapy compared to convention al methods. This has been best demonstrated by [CONTACT_910205] 3- D conformal 
planning. Nonetheless, even with IMRT planning, currently accepted standards for radiotherapy volumes based on location of gross disease still incorporate tissues critical to swallowing. Long -
term dysphagia is increasingly recognized as having a major impact on quality of life in patients treated with curative intent concurrent chemoradiotherapy. Therefore, strategies that would preserve the survival gains achieved with chemoradiotherapy while improving long- term 
function are needed. 
Alliance A091101  
 
Version Date: 08/11/2017  9 Update #07  2.2 Patterns of Failure in LAHNC  
A retrospective analysis of 5-FU, hydroxyurea and radiotherapy ( FHX) trials utilizing intensive 
concomitant chemoradiotherapy conducted from [ADDRESS_1277782] failure pattern based on TNM staging. That is, patients with T4 tumors tended to fail locally while those with N2 or N3 disease failed distantly, usually in the lungs.
6 Distant 
failure in these patients is devastating, as there is no op portunity for salvage with either surgery 
or re-irradiation, supporting the importance of a potentially lower distant failure rate associated 
with the introduction of induction chemotherapy (neoadjuvant). 
2.3 Induction Chemotherapy  
Recently, the addition of neoadjuvant (induction) chemotherapy has garnered interest with the 
completion of phase 3 studies demonstrating the a ctivity and efficacy of a three drug regimen 
consisting of cisplatin, 5FU, and a taxane (TPF). TPF induction chemotherapy is effective but 
is associated with significant toxicity especially myelosuppression and mucositis.  
Induction chemotherapy has been under investigation for more than two decades in locally 
advanced squamous cell carcinoma of the head and neck.  Most regimens are used fo r [ADDRESS_1277783] of drugs with documented single agent activity in patients with recurrent disease (i.e., methotrexate, cis - or carboplatin, 5- fluorouracil, bleomycin, paclitaxel, docetaxel). 
High overall response rates exceeding 80% and complet e response (CR) rates ranging from 20 
to 54% have been reported. Some of these will be histologically confirmed at surgery. Achieving 
a complete response (CR) to chemotherapy, particularly if confirmed histologically, correlates 
with a good prognosis; and patients not responding to induction chemotherapy generally are unlikely to respond to subsequent standard radiotherapy; the administration of chemotherapy 
generally does not jeopardize the administration of subsequent standard local therapy.  
There is incr easing evidence suggesting that systemically active chemotherapy may prevent 
recurrences at distant sites. Distant recurrence after the eradication of the primary tumor and 
locoregional disease is presumably due to micrometastatic disease that the lower doses of 
chemotherapy administered as a component of chemoradiotherapy do not adequately treat. Even 
though in early trials a survival benefit could not be found, serious methodological deficiencies 
limit these trials (inadequate design, substandard local therapy, etc.). 
Induction chemotherapy continues to be frequently used in centers around the world and 
represents a good trial approach to investigate novel therapi[INVESTIGATOR_13265]/or molecular correlates. In 
recent years randomized trials have further substantiated the finding that induction chemotherapy including a taxane and cisplatin can increase survival rates. Induction 
chemotherapy can produce CR rates in 30–65% of patients and overall response rates of 70 –
85%. Two newer European studies have shown evidence of a survival bene fit with induction 
chemotherapy: the Italian GSTTC study (Gruppo di Studio sui Tumori della Testa) demonstrated 
increased cure rates in a subset of nonoperable subjects and the French GETTEC trial (Groupe 
d’Etude des Tumeurs de la Tete et du Cou), which wa s closed early due to clear benefit. 
Furthermore a large meta- analysis by [CONTACT_25715][INVESTIGATOR_910182] a 5% increase in survival only 
for trials using a cisplatin/fluorouracil (5 -FU) combination, reaching statistical significance 
(P<0.05). 
In addition, two trials comparing the triplet combination of a taxane (docetaxel or paclitaxel), 
cisplatin, and 5 -FU (TPF) with doublet cisplatin/5 -FU (PF) showed a survival benefit of the 
triplet over the doublet combination. However, the high rates of toxicity reported in TAX 323 and TAX 324 led many oncologists to question the feasibility of TPF. In TAX 324, 21% of 
patients did not proceed to protocol -defined chemoradiotherapy and 7% of patients did not 
proceed to potentially curative therapy.
7,9 Carboplatin and paclitaxel were used together in a 
phase II study consisting mainly of stage IV patients where a clinical complete RR of 100%, 3 -
Alliance A091101  
 
Version Date: 08/11/2017  10 Update #07  year OS of 70% and a 3 -year progression -free survival (PFS) of 90% were demonstrated 
following completion of definitive chemoradiotherapy.12 Although the regimen was less toxic 
compared with TPF, RR to induction chemotherapy was preserved; RR to TPF in TAX 323 and 
TAX 324 was 68 and 72%, respectively. The single institution experience of our center comparing induction chemotherapy with carboplatin and paclitaxel (CT) with TPF showed that 
the 1 year locoregional control was 80.5% for CT compared to 55.5% for TPF (HR 
0.32,P = .0002).
53 The 1  year progression free survival was 73.2% for CT compared to 60.7% 
for TPF (H R 0.57;P  = .02). On multivariable analysis, CT remained significant for LRC (HR 
0.28; P = 0.04). TPF induction chemotherapy was associated with worse renal toxicity as 
measured by [CONTACT_910206] (P  = 0.001). TPF was  
also associated with a trend toward more chemotherapy dose reductions or changes in systemic agents during concurrent chemoradiotherapy (43.4% for TPF vs. 27.8% for CT;  P = 0.06). 
Further evidence to support not using TFP in this clinical trial comes from  an early version of 
this phase 1 protocol, where three patients with locally advanced disease were treated with ABT -
888 40mg bid and TPF. Remarkably, all three patients developed neutropenic fever, what would 
require dose reductions, even at supposedly low doses of ABT -888 (40mg bid). To justify this 
statement, the ABT -[ADDRESS_1277784] demonstrated that 
induction chemotherapy with carboplatin –paclitaxel provided a complete response rate and 
partial response rate from 8% to 33% and from 50% to 85%, respectively.
54-58 Furthermore, the 
PFS and OS were consistently between 60- 80%. In many of these prospective series, patients 
tolerated CT and subsequent concurrent chemoradiotherapy with minimal additional toxicity. 
This protocol thus elected to use carboplatin -paclitaxel as the induction chemotherapy regimen.  
Carbopla tin is a c omm only used platinum compound that acts by [CONTACT_910207] n.  It is approved by [CONTACT_941] F DA for the treatment of pa tients with 
ovarian cancer. It is also used for the  treatment of non -small cell lung cancer , sma ll cell lung  
cancer, head and nec k canc er, endometrial cancer, meta static seminoma and more recently 
in brea st cancer. C arbopla tin is elimin ated b y renal ex cretion. T he clearance is related to the 
glomerular f iltration rate. Therefore  it is dos ed based on the GFR a nd the t arget are a under the 
concentration versus  time cur ve (AUC). The ma in side effect of carbopla tin is 
myelosuppre ssion. Oth er toxicities in clude naus ea, vomi ting, renal a nd neurotoxicity. 
2.4 Concurrent chemoradiotherapy  
Results  of many  recently  published phase  III trials 
show  that chemotherapy given  concurrently 
with radiation  yields  better  LRC and survival  rates than radiation  alone in patients with locally 
advanced  squamous cell carcinoma of the head and neck ( SCCHN ).1-5 
2.4.1 Concurrent accelerated radiotherapy and cisplatin  
The Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940) is the most recent 
Cooperative group trial that showed benefit of concurrent accelerated radiotherapy and cisplatin (AFX -Cis).
5 The primary objective of this study was to evaluate whether the 
addition of cetuximab to cisplatin would improve disease -free survival. Secondly, the study 
assessed overall survival, local -regional control, acute and late toxicities and quality of life. 
It showed no benefit to adding cetuximab to the radiation/cisplatin platform for front -line 
therapy of advanced head and neck squamous cell carcinoma. At 2 years, progression -free 
survival was approximately 64% in both arms; overall surviv al was 79.7% with 
chemoradiotherapy ( P = .68) and 82.6% with the addition of cetuximab ( P = .17). Rates of 
locoregiona l relapse and distant metastases were also similar. However, cetuximab 
increased grade 3/4 mucositis (43% vs 33%; P < .004), in- field skin toxicity (25% vs 
15%; P < .001), and out -of-field skin reactions (19% vs 1%; P < .001), but toxicity beyond 
Alliance A091101  
 
Version Date: 08/11/2017  11 Update #[ADDRESS_1277785] continued to use the hydroxyurea, 5- FU, p aclitaxel and radiotherapy ( TFHX) regimen 
as previously defined. Despi[INVESTIGATOR_910183], three 
problems were identified: distant failure emerged as the predominant site of failure, 
mucositis was often severe and sometimes resulted in long -term functional impairment, and 
toxicities related to chemotherapy (specifically neuropathy and myelosuppression) often 
resulted in dose reduction and patient impairment. To address the first problem , we added 
induction chemotherapy to precede concomitant chemoradiotherapy. In designing the induction chemotherapy regimen, we selected the combination of carboplatin and paclitaxel, 
a regimen that is well tolerated and that would not result in mucositis or dermatitis as significant toxicity to avoid overlappi[INVESTIGATOR_910184].  
 We also addressed the second goal of reducing toxicity and improving functional 
performance. The exceedingly high local and regional control rates observed in all T FHX 
studies suggested that a careful attempt to reduce the radiation therapy field sizes to 
minimize long- term treatment sequelae would be feasible.  The results of this trial 2 
involving 69 patients revealed response to induction chemotherapy to be PR 52% and CR 
35%. Symptomatically, there was a significant reduction in mouth and throat pain. The most 
common grade 3 or 4 toxicity was neutropenia (36%)  while 33% of patients experienced 
neuropathy. Best res ponse following completion of TFHX was CR in 83%. Toxicities of 
TFHX consisted of grade 3 or 4 mucositis (74% and 2%), and dermatitis (47% and 14%). 
At a median follow up of [ADDRESS_1277786] each 
been noted in five patients. The overall three year progression -free survival is 80% (95% 
confidence interval (CI): 71% -90%) and the two and three year overall survival rates are 
77% (95% CI: 66% -87%) and 70%, (95% CI : 59% -82%), respectively. At 12 months, 5 
patients were completely feeding tube dependent (patients who died without disease progression were censored from the PFS analysis). Similar results were reported in two follow- up studies using the TFHX platform.
[ADDRESS_1277787] chemoradiotherapy regimen to follow novel investigational induction chemotherapy regimens.  
2.4.3 Radiotherapy  
Radiotherapy doses currently employed during concurrent chemoradiotherapy are la rgely 
empi[INVESTIGATOR_910185]. The gross tumor volume (GTV) includes all known gross 
disease detected on physical or radiographic examination both at the primary and neck before. Planning target volume 1 (PTV1) includes the GTV plus a 1.[ADDRESS_1277788] echelon of uninvolved lymph nodes. The PTV1 is a margin of 
error around visible tumor and this area receives the maximum dose  of radiotherapy. In 
addition, areas at risk for microscopic disease encompassing draining lymph nodes are also treated and usually include bilateral cervical lymph node stations. In a subset analysis of data assessing disease recurrence from multi -institu tional studies administering FHX -based 
chemoradiotherapy, it became apparent that locoregional failures overwhelmingly occurred in PTV1. This was especially true in subjects who attained a complete response to induction 
chemotherapy where no failures were recorded outside PTV1 in these patients. However, 
Alliance A091101  
 
Version Date: 08/11/2017  12 Update #[ADDRESS_1277789] risk for this event is paramount.  
Prior published studies at  the University of Chicago  indicate that advanced nodal stage is a 
predictor for the development of distant metastatic disease after aggressive concurrent chemoradiotherapy
6. In addition, there is also evidence that T stage, or local extension of the 
tumor, is also a predictor of distant failure after concurrent chemoradiotherapy.11 Thus, nodal 
and T -stage will be used to stratify patients at randomization into low versus high risk groups 
for distant metastases. (T1 -3 and N0 -N2a versus N2b -.N3 and/or T4, respectively ).  
Given the fa ct that institutions will be able to select between 2 different chemoradiotherapy 
regimens prior to treating their patients, patients will be also stratified by [CONTACT_262516].  
2.5.1 Oropharyngeal cancer and Human papi[INVESTIGATOR_28597] (HPV) 
The presence of  HPV DNA is strongly associated with oropharynx cancer and thought to be 
an etiologic agent. Patients with HPV positive oropharynx cancer not only appear to have a different clinical phenotype than HPV - cancers but multiple large studies have demonstrated 
a better outcome for these patients even when correcting for other known prognostic factors.
12 Thus, patients with HPV+ oropharynx cancer, compared to their HPV - 
counterparts, demonstrate higher response rates to induction chemotherapy, better 
locoregional control when treated with concomitant chemoradiotherapy, and better overall 
survival. Interestingly, tobacco exposure, especially greater than [ADDRESS_1277790] of HPV positivity on outcomes and increases the risk of disease 
recurrence and mortality. Patients with HPV+ oropharynx cancer with significant tobacco 
exposure (>10 pack- years) appear to have an intermediate risk of dying from disease 
between HPV+/non-smokers and HPV- patients. Therefore, the outcome of any therapeutic 
approach must now be evaluated in the context of subject HPV status while some 
investigators have advocated for clinical trials de- intensifying treatment to HPV+ patients.  
A recently reported large phase III trial of the Radiation Therapy Oncology Group (R TOG 
0129) revealed no differences in the overall survival (OS) and progression free survival 
(PFS) rates between accelerated fractionation and standard fractionation when combined 
with concurrent high- dose cisplatin.[ADDRESS_1277791], independent prognostic factor in patients treated with 
radiation -cisplatin regimen. In addition, the investigators wer e able to divide patients into 
categories of low, intermediate or  high risk of death based on HPV status, smoking history, 
and tumor stage.  
Recursive- partitioning analysis showed that the HPV status of the tumor was the major 
determinant of overall surviv al, followed by [CONTACT_789127]- years of tobacco smoking 
(≤10 vs. >10) and then nodal stage (N0 to N2a vs. N2b to N3), for HPV- positive tumors, or 
tumor stage (T2 or T3 vs. T4), for HPV -negative tumors. Their analysis classified patients 
with oropharyngeal squamous -cell carcinoma into three categories with respect to the risk 
of death: low risk, with a 3- year rate of overall survival of 93.0%; intermediate risk, with a 
3-year rate of 70.8% (hazard ratio for the comparison with low risk, 3.54; 95% CI, 1.91 to 
6.57); and high risk, with a 3- year rate of 46.2% (hazard ratio for the comparison with low 
Alliance A091101  
 
Version Date: 08/11/2017  13 Update #07  risk, 7.16; 95% CI, 3.97 to 12.93). Patients with HPV -positive tumors were considered to 
be at low risk, with the exception of smokers with a high nodal stage (i.e., N2b to N3), who 
were considered to be at intermediate risk; patients with HPV -negative tumors were 
considered to be at high risk, with the exception of nonsmokers with tumors of stage T2 or 
T3, who were considered to be at intermediate risk.  
Risk-stratification algorithms based on biomarkers, especially HPV status, in LAHNC have 
recently been incorporated into clinical trials. The option that CRT and the addition of 
biologics should focus on HPV -negative patients, and that for HPV -positive patients,  
researchers should look at less intense options that might spare these patients some of the 
long- term morbidities of CRT (mainly the radiotherapy component) is very attractive. This 
approach has been studied by [CONTACT_64850] (ECOG ) - trial 
ECOG 1308 - targeting specifically HPV -positive patients, and the Radiation Therapy 
Oncology Group (RTOG), with both groups assessing the addition of cetuximab. 
In order to differentiate low risk patients from others, we will be applying similar 
classification  criteria for study inclusion, based on Ang et al.12 Please notice we will be 
adding non- OPC tumors as high -risk and dividing the patients into 2 groups: low -risk and 
high-risk. We will be condensing the original Ang et al “intermediate and h igh-risk groups” 
into a high risk group, given the similarity of the confidence intervals of overall survival, as 
below. 
The 3 -year rates of overall survival were 93.0% (95% CI, 88.3 to 97.7) in the low -risk group, 
70.8% (95% CI, 60.7 to 80.8) in the inter mediate -risk group, and 46.2% (95% CI, 34.7 to 
57.7) in the high-risk group. Adapted from Ang et al.12 
In summary, the risk classification  criteria used for study inclusion will be: 
Low risk L ocally Advanced H ead and Neck Cancer (LAHNC) , not eligible for study 
inclusion:  
• Oropharyngeal cancer (OPC), HPV positive , with less than 10 pack year smoking history  
(any nodal status) 
• OPC , HPV positive, with at least  a 10 pack year smoking history, and N0 -N2a disease  
High risk LAHNC:  
• Stage IVa -b Squamous C ell Carcinoma (SCC)  other than OPC, OR  
• OPC , HPV negative, Stage IVa- b SCC  
• OPC , HPV positive with at least a [ADDRESS_1277792] their tumor  HPV status (either positive or 
negative) prior to stratification.  There is currently no standard approach for HPV testing of 
clinical samples and, as such, individual institutions can determine the tumor HPV status by 
[CONTACT_910208]. Acceptable methods of determination include: 
• P16 by [CONTACT_9064] (IHC) as a surrogate for the function of the high- risk 
(HR) HPV E7 protein.  
• HPV 16 insitu hybridization (ISH) 
• HPV DNA detection by [CONTACT_940] (PCR) 
Alliance A091101  
 
Version Date: 08/11/2017  14 Update #07  2.6 ABT -888 (Veliparib) 
ABT-888 is an orally available, small molecule inhibitor of poly(ADP -ribose) polymerase 
(PARP).  PARP is an essential nuclear enzyme that plays a role in recognition of DNA damage 
and facilitation of DNA repair.  Therefore, inhibition of PARP is expected to enhance the effects 
of DNA damage.  Expression of PARP is higher in tumor cells as compared to normal cells.  This 
overexpression has been linked to drug resistance and the ability of tumor cells to withstand 
genotoxic stress.  Hence, it is anticipated that PARP inhibitors will function as sensitizing agents 
for chemotherapy and radiation therapy that are designed to cause DNA damage. 
2.6.1 Mechanism of Action  
Poly (ADP -ribosyl)ation (PAR) occurs after single or double -stranded DNA damage and 
represents the  posttranslational modification of histones and other nuclear proteins by [CONTACT_119547].  
Based on conserved genetic sequences, encoded for by [ADDRESS_1277793] been classified as members of the PARP superfamily.  The superfamily is 
furth er subdivided into three branches, the PARP -1 group, the tankyrase group, and other 
PARP enyzmes.  The PARP -1 group of NAD+-dependent enzymes has been extensively 
studied, and its members PARP -1 and PARP -2 are generally considered as the primary 
enzymes in volved in DNA repair 13. 
PAR has been implicated in many cellular processes including replication, transcription, 
differentiation, gene regulation, protein degradation, and spi[INVESTIGATOR_52334].  Enhanced 
PARP -1 expression and/or activity in tumor cells, as  compared to normal cells, has been 
demonstrated in malignant lymphomas 14, hepatocellular carcinoma 15, cervical carcinoma 
16, colorectal carcinoma 17, non- Hodgkin's lymphoma 18, leukemic lymphocytes 19, and colon 
adenomatous polyps 20.  PARP -1 and PARP -2 are nuclear proteins and are the only members 
of the PARP family with zinc -finger DNA binding domains.  These domains localize PARP -
1 and PARP -2 to the site of DNA damage.  PARP- 1 is highly conserved and has three 
structural domains (N -terminal DNA -binding domain; automodification domain, and the 
NAD+-binding domain).  The catalytic domain is located at the C -terminus end of the 
protein.  In knockout mouse models, deletion of PARP- 1 is sufficient to impair DNA repair 
21-23.  The residual PARP- dependent repair activity (~ 10%) is due to PARP -2.  This suggests 
that only PARP-1 and PARP-2 need to be inhibited to impair DNA repair 24-26. 
The zinc finger domain of PARP binds to both single - and double -stranded DNA breaks, 
resulting in increased catalytic activity 24,26,27.  Once activated, PARP cleaves NAD+ and 
attaches multiple ADP -ribose units to the target nuclear protein. This results in a highly 
negative charge on the target protein and affects its function.  Overactivation of PARP can 
be induced by [CONTACT_910209], leading to the depletion of NAD+ and energy stores and, thus, 
cellular demise by [CONTACT_372329].  An alternate mechanism has been identified where PARP 
overactivation can induce cell death through apoptosis by [CONTACT_910210] (AIF) from mitochondria 28.  Consequently, multiple mechanisms to prevent 
overactivation of PARP exist.  First, auto -PAR negatively regulates PARP activity 29.  In 
addition, the cleavage of PARP by [CONTACT_372331] a peptide fragment that acts as a trans-dominant negative inhibitor for uncleaved PARP.  PAR of proteins is a dynamic process with 
a short half -life (t
1/2) of <1 min.  The enzymes responsible for degrading these polymers are 
poly(ADP -ribose) glycohydrolase (PARG), which cleaves ribose- ribose bonds, and AD P-
ribosyl protein lyase, which removes the protein proximal to the ADP-ribose monomer. 
Increased PARP activity is one of the mechanisms by [CONTACT_52363].  PARP activity is essential for the repair of single- stranded 
DNA breaks through the base excision repair (BER) pathways 26,30. Therefore, inhibition of 
PARP sensitizes tumor cells to cytotoxic agents (e.g. alkylators [temozolomide, 
Alliance A091101  
 
Version Date: 08/11/2017  15 Update #07  cyclophosphamide, BCNU] and topoisomerase I inhibitors [irinotecan, camptothecin, 
topotecan]) which induce DNA damage that would normally be repaired through the BER 
system.  A significant therapeutic window appears to exist between a PARP inhibitor’s 
ability to potentiate therapeutic benefit versus potentiation of undesirable si de effects.  As 
expected, PARP inhibitors do not potentiate agents that do not cause DNA damage. 
Ionizing radiation induces both double - and single -stranded DNA breaks.  While part of the 
radiosensitization caused by [CONTACT_372333] -stranded 
break repair pathways, it appears likely that repair of double -stranded  breaks, which are 
thought to be more cytotoxic, is also affected.  Double -stranded breaks are strong activators 
of PARP -1, resulting in PARP -1 mediated activation of DNA -PK and Ku80, important 
components of the non- homologous end -joining (NHEJ) double -stranded break repair 
pathway 31,32.  Also, small molecule inhibitors of PARP can directly inhibit the repair of 
double- stranded breaks 21,33.  Thus, it is likely that PARP activity is important for repair of 
both the single- and double-stranded stranded DNA breaks caused by [CONTACT_22256]. 
2.6.[ADDRESS_1277794] of ABT -888 in 
combination with cytotoxic agents on DNA damage, the cellular content of γ-H2AX in C -
41 cells was assayed by [CONTACT_622761] -γ-H2AX antibody.  Addition of 1 mM 
of temozolomide alone resulted in increased numbers of γ-H2AX foci, a result which was 
further potentiated by [CONTACT_345040] -888 in a dose -dependent manner.  When cell survival was 
measured by [CONTACT_372336], ABT -888 potentiated cytotoxicity in the same 
concentration range  as used in the γ-H2AX assay, demonstrating that ABT -888 potentiates 
cytotoxicity of temozolomide by [CONTACT_372337].  ABT -888 achieved a maximal 
potentiation of approximately 15-fold.  ABT- 888 also potentiates the DNA damage cause 
by [CONTACT_372338]. 
 
 
 
 
PARP inhibition was shown to sensitize cells that are 
mismatch repair (MMR) -deficient to a greater extent than cells that are MMR competent 34.  
Alkylating agents such as temozolomide form methyl adducts in DNA and resistance is 
frequently encountered in the clinic with either the overexpression of O6-alkylguanine DNA 
alkyltransferase (AGT) or functional defects in the MMR system.  However, when PARP was inhibited, cells were sensitized to methylpurine formation, regardless of their resistance factors 
35. 
There are data to suggest that PARP inhibitors have activity against some BRCA -deficient 
cells in the absence of any DNA damag ing agent 36,37.  These inhibitors did not demonstrate 
single agent activity in BRCA -competent cells, and restoring functional BRCA to deficient 
cells abrogated single agent cytotoxicity.  It is possible that, in BRCA -deficient cells, PARP 
inhibition stops  the BER pathway, and thus single -stranded breaks are carried through DNA 
synthesis, resulting in double- stranded breaks.  The increase in double- stranded breaks 
cannot be repaired by [CONTACT_10579] (HR), due to the lack of BRCA1 or 2, 

Alliance A091101  
 
Version Date: 08/11/2017  16 Update #[ADDRESS_1277795] that PARP inhibitors 
sensitize cancer cells to radiation, both in vitro and in vivo 40-42.  Furthermore, a PARP 
inhibitor in the same class as ABT -888 potentiated radiation in the HCT116 colon 
carcinoma model.  ABT -888 was tested, in combination with cytotoxic agents, in several 
tumor models and demonstrated a similar profile of antitumor activity to that seen in the literature .  ABT -888 substantially increased the efficacy of cytotoxic therapi[INVESTIGATOR_014], when 
measured by [CONTACT_372339]/control tumor volumes (%T/C) or by [CONTACT_372340] a particular size (%ILS).  
  
Alliance A091101  
 
Version Date: 08/11/2017  17 Update #07   
 
  
 
  
 
  
  
 
 
     
     
     
     
     
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101  
 
Version Date: 08/11/2017  18 Update #07   
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
   

Alliance A091101  
 
Version Date: 08/11/2017  19 Update #07   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101  
 
Version Date: 08/11/2017  20 Update #07   
 
   
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
2.6.4  C
linical Investigations  
A single -dose pharmacokinetic and pharmacodynamic endpoint study in cancer patients was 
initiated under an exploratory IND by [CONTACT_910211] 0 program (Kummar et al. , 2009).  In this study, participants had baseline 
assessments of PAR in peripheral blood mononuclear cells (PBMCs) and at higher dose levels, in tumor from needle biopsies, assessed by a validated immunoassay.  Participants 
received a single dose of ABT -[ADDRESS_1277796] 4 hours at the 25 mg dose level.  Leve ls of PAR were reduced 80 -99% from baseline levels after administration of ABT -[ADDRESS_1277797] recently, a phase I trial of ABT -888 with 
doxorubicin(A) and cycyphosphamide ( C) was reported.
44 ABT -888 (doses ranged from 50 
to 150 mg every 12 h on days 1 - 4 with fixed dosing of AC (60/600 mg/m2) on day 3 every 
21 days. Further A was omitted after a cumulative dose of 420 mg/m2. The MTD of ABT -
888 was 100 mg every 12 h with AC every 21 days. Two instances of grade 3 febrile neutropenia were considered dose- limiting at the 150 mg ABT -888 dose level. MTD of 
ABT -888 was 100 mg every 12 h with AC. Drug -related toxicities included fatigue and 
myelosuppression.  
Another phase I study sought to evaluate ABT -888 with irinotecan in solid tumors.
45 Cycles 
were administered every 21 days. Irinotecan was given intravenoulsy. 100 mg/m2 over 90 

Alliance A091101  
 
Version Date: 08/11/2017  21 Update #07  min on Days 1 and 8. Twice daily (BID) oral dosing of ABT -888 (10- 50mg) occurred  on 
days 3 -14  (Cyc le 1) and Days -1-14 (subsequent cycles) followed by a 6- day rest. The MTD 
and recommended phase II dose was established as 100 mg/m2 of irinotecan given days 1 
and 8 combined with 40 mg of ABT -888 given BID 15 days on/[ADDRESS_1277798] f requent drug -related toxicities included: diarrhea (59%), nausea (56%),  leukopenia 
(50%), fatigue (47%), neutropenia (47%), anemia (34%), and vomiting (31%). DLTs 
included fatigue, diarrhea, febrile neutropenia (grade 3), leukopenia and, neutropenia (grade  
4). 
Further detailed information regarding ABT -888 clinical development, safety and efficacy 
is provided in the Investigator’s Brochure. 
2.[ADDRESS_1277799] with additional clinical trials in other tumors about to be initiated. The 
concept of “synthetic lethality” that is blocking a repair pathway in tumors that are defective in 
another repair pathway has become an important model for the use of PARPi [INVESTIGATOR_910186]. Patients defective in BRAC1 and BRAC2 mediated homologous repair 
are proposed to be sensitive to PARPi [INVESTIGATOR_910187]-homologous repair pathway.  
However the therapeutic effects of PARPi [INVESTIGATOR_910188]1 and BRAC2 mutations is fairly modest pointing to combination therapy as the most promising direction for 
the use of PARPi. In general tumor cell death achieved through the interaction of PARP 
inhibition with chemotherapy and radiotherapy is proposed to occur through mitotic (necrotic) or apoptotic cell death. A novel set of data underpi[INVESTIGATOR_910189] -tumor effects especially in tumor cells resistant to necrotic 
or apoptotic death. We propose that accelerating  DNA damage induced senescence by [CONTACT_246097] 
[INVESTIGATOR_443875] a novel approach to cancer therapy. The hypothesis is that the addition of a PARP inhibitor (ABT -888) to induction chemotherapy for LAHNC will be feasible and lead to 
measureable differences in clinical outcome parameters, especially complete (or near complete) response rate, as well as correlate with expression of cellular targets and potential biomarkers.  
2.8 Correlatives Studies Background  
PARP is a nuclear enzyme that recognizes DNA damage and facilitates DNA repair.
26,46,47 
Activation of PARP -1 and PARP -2 enzymes is an essential step in the recognition of DNA 
damage that results in the poly(ADP -ribosyl)ation of many nuclear target proteins, including 
those that facilitate DNA repair. DNA repair pathways can be divided into those that involve single -stranded DNA breaks and those that involve double -stranded DNA breaks. PARP activity 
is essential for the repair of single -stranded DNA breaks through the Base Excisional Repair 
(BER) pathways.
18,30,48 PARP activ ity also has been demonstrated to be an important modulator 
of the nonhomologous end- joining and homologous recombination double -stranded break repair 
pathways. Consequently, inhibition of PARP should enhance the effects of DNA -damaging 
Alliance A091101  
 
Version Date: 08/11/2017  22 Update #[ADDRESS_1277800] longer than without ABT 888. 
γ-H2AXand poly  (ADP -ribose) as suggested by [CONTACT_910212]., 2010:  tumor cells are often 
deficient in DNA damage response (DDR) pathways, and anticancer therapi[INVESTIGATOR_910190]/or drug s that damage DNA directly or 
interfere with DNA metabolism, leading to the formation of DNA double -strand breaks (DSB), 
and ultimately to cell death. Because DSBs induce the phosphorylation of histone H2AX (γH2AX) in the chromatin flanking the break site, an antibody directed against γH2AX can be 
employed to measure DNA damage levels before and after patient treatment. Poly(ADP -ribose) 
polymerases (PARP1 and PARP2) are also activated by [CONTACT_910209], and PARP inhibitors show promising activity in cancers with defective homologous recombination (HR) pathways for DSB 
repair.  
Other markers of value in SCCHN or determinants of sensitivity to PARP inhibitors, including 
testing for EGFR, MET and p16 (HPV) expression and analysis of PTEN, P16 and BRCA1 mutations wil l also be analyzed.  
Alliance A091101  
 
Version Date: 08/11/2017  23 Update #07  3.0 PATIENT  SELECTION  
3.1 Eligibility Criteria for Phase 1 Component 
3.1.1  Documentation of Disease: Patients who are treatment naïve,  high risk , stage IVa/IVb (all 
other sites) and histologically proven squamous cell carcinoma of the  head and neck 
(SCCHN ) with no definitive evidence of metastatic disease, excluding patients with 
oropharynx HPV-positive tumors. 
 In summary, those patients eligible are newly diagnosed and treatment naive:  
• Stage IVa- b Squamous C ell Carcinoma other than Oropharyngeal Cancer ( OPC ), OR 
• Oropharyngeal Cancer (OPC) HPV- negative, Stage IVa-b 
3.1.2 Measurable Disease: Patients must have at least one measurable site of disease according 
to RECIST criteria. i.e., patients must have measurable disease, defined as at least one lesion 
that can be accurately measured in at least one dimension (longest diameter to be recorded 
for non- nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional 
techniques or as ≥[ADDRESS_1277801] scan MRI,  or calipers by [CONTACT_461].  See Section 
11.2 for the evaluation of measurable disease.  
3.1.3  ECOG performance status 0 -1.   
3.1.4 Age >[ADDRESS_1277802] be able to swallow the drug.  
3.1.6  Ability to understand and the willingness to sign a written informed consent document. 
3.1.7 Required Lab Values:  
leukocytes  ≥ 3,000/ mm3 
absolute neutrophil count  ≥ 1,500/  mm3 
platelets  ≥ 100,000/  mm3 
total bilirubin  ≤ 1.5 Institutional upper limit of normal (ULN)  
SGOT(AST) and SGPT(ALT)  ≤ 2.[ADDRESS_1277803]  
creatinine clearance  ≥ 60 mL/min/1.[ADDRESS_1277804] * 
* As calculated by [CONTACT_3158]- Gault.  
3.1.8  Patients who are receiving any other investigational agents are not eligib le.  
3.1.9 Patients with active seizure or a history of seizure are not eligible.  
3.1.10 Patients with a  history of allergic reactions attributed to compounds of similar chemical or 
biologic composition to ABT -888 or other agents used in study, including cremo phor, 
carboplatin, paclitaxel , cisplatin, 5-f luorouracil, hydroxyurea, or any compounds of similar 
chemical or biologic composition are not eligible.  
3.1.11  Patients with i mpairment of gastrointestinal function or gastrointestinal disease that may 
significantly alter the absorption of ABT -888 (e.g., ulcerative disease, uncontrolled nausea, 
vomiting, diarrhea, malabsorption syndrome or small bowel resection) are not eligible to 
participate in this study. 
Alliance A091101  
 
Version Date: 08/11/2017  24 Update #07  3.1.12 Patients with u ncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that would limit compliance with study 
requirements  are not eli gible to participate in the study . 
3.1.13 Pregnant women are not eligible to participate in this study . NOTE: Women of child 
bearing potential must have a negative serum or urine pregnancy test within 7 days prior to 
treatment . ABT -888 is a PARP inhibitor with the potential for teratogenic or abortifacient 
effects.  
• Women of child- bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is 
pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.  
• Because there is an unknown but potential risk for adverse events in nur sing infants 
secondary to treatment of the mother with ABT -888, breastfeeding should be 
discontinued if the mother is treated with ABT -888. These potential risks may also 
apply to other agents used in this study. 
3.1.[ADDRESS_1277805] 2 years, except for adequately treated 
carcinoma of the cervix or basal or squamous cell carcinomas of the skin or surgically 
treated ear ly stage solid tumors are ineligible to participate in this study.  
3.2 Eligibility Criteria for Phase 2 Component 
3.2.1 Documentation of Disease: Patients who are treatment naïve,  high risk, stage IVa/IVb (all 
other sites) histologically proven S quamous C ell Carcinoma of the Head and Neck 
(SCCHN)  with no definitive evidence of metastatic disease. 
In summary , those patients eligible are : 
• Stage IVa -b SCCHN other than oropharyngeal Cancer (OPC) , OR  
• OPC , HPV -negative, IVa-b, OR 
• OPC , HPV positive , with g reater than 10 pack- year smoking history and N2b- N3 
disease  
3.2.2 Measurable disease: Patients must have at least one measurable site of disease according 
to RECIST criteria. i.e., patients must have measurable disease, defined as at least one lesion 
that can be accurately measured in at least one dimension (longest diameter to be recorded 
for non- nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional 
techniques or as ≥[ADDRESS_1277806] scan MRI, or calipers by [CONTACT_461].  See Section 
11.2 for the evaluation of measurable disease.  
3.2.3 ECOG performance status 0-1. 
Alliance A091101  
 
Version Date: 08/11/2017  25 Update #07  3.2.4 Age ≥[ADDRESS_1277807] be able to swallow the drug . 
3.2.6 Ability to understand and the willingness to sign a written informed consent document. 
3.2.7 Required Lab Values:  
leukocytes  ≥ 3,000/ mm3 
absolute neutrophil count  ≥ 1,500/  mm3 
platelets  ≥ 100,000/  mm3 
total bilirubin  ≤ 1.5 Institutional upper limit of normal (ULN)  
SGOT( AST ) and SGPT  
(ALT ) ≤ 2.[ADDRESS_1277808]  
creatinine clearance  ≥ 60 mL/min/1.[ADDRESS_1277809] * 
* As calculated by [CONTACT_3158]- Gault.  
3.2.8 Patient History: Patients who are receiving any other investigational agents are not eligible.  
3.2.9 Patients with active seizure or a history of seizure are not eligible.  
3.2.10 Patients with a  history of allergic reactions attributed to compounds of similar chemical or 
biologic composition to ABT -888 or other agents used in study, including cr emophor, 
carboplatin, pa clitaxel , cisplatin, 5 -fluorouracil, hydroxyurea, or any compounds of similar 
chemical or biologic composition are not eligible.  
3.2.11  Patients with i mpairment of gastrointestinal function or gastrointestinal disease that may 
significantly alter the absor ption of ABT -888 (e.g., ulcerative disease, uncontrolled nausea, 
vomiting, diarrhea, malabsorption syndrome or small bowel resection) are not eligible to 
participate in this study. 
3.2.12 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, 
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or 
psychiatric illness/social situations that would limit compliance with study requirements  are 
not eligible to participate in this study . 
3.2.13 Pregnant women are not eligible to participate in this study.  NOTE: Women of child 
bearing potential must have a negative serum or urine pregnancy test within 7 days prior to 
treatment . ABT -888 is a PARP inhibitor with the potential for teratogenic or abortifacient 
effects.  
• Women of child- bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study entry and for 
the duration of study participation. Should a woman become pregnant or suspect she 
is pregnant while she or her partner is participating in this study, she should inform her 
treating physician immediately.  
• Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ABT -888, breastfeeding should be 
discontinued if the mother is treated with ABT -888. These potential risks may also 
apply to other agents used in this study. 
3.2.14 HIV-positive patients on combination antiretroviral therapy  are not eligib le because of the 
potential for pharmacokinetic interactions with ABT-888.  
Alliance A091101  
 
Version Date: 08/11/2017  26 Update #[ADDRESS_1277810] 2 years, except for adequately treated 
carcinoma of the cervix or basal or squamous cell carcinomas of the skin or surgically 
treated early stage solid tumors are ineligible to participate in this study.  
3.3 Inclusion of Women and Minorities   
Both men and women of all races and ethnic groups are eligible for this trial.  
4.0 REGISTRATION/RANDOMIZATION  PROCEDURES  AND  STRATIFICATION 
Informed Consent   
The patient must be aware of the neoplastic nature of his/her  disease and willingly consent after being 
informed of the procedure to be followed, the  experimental nature of the therapy, alternatives, 
potential benefits, side effects, risks,  and discomforts. Human protection committee approval of this 
protocol and a consent form are required.  
Registration must occur prior to the initiation of therapy.  
OPEN  Access Requirements  
• Site staff will need to be registered with CTEP and have a valid and active CTEP -IAM 
account. This is the sam e account (user id and password) used for the CTSU members' web 
site. 
• To perform registrations, the site user must have been assigned the 'Registrar' role on the 
relevant Group or CTSU roster.  
• To perform registrations on protocols for which you are a m ember of the Lead Group, you 
must have an equivalent 'Registrar' role on the Lead Group roster. Role assignments are 
handled through the Groups in which you are a member.  
• To perform registrations to trials accessed via the CTSU mechanism (i.e., non -Lead  Group 
registrations) you must have the role of Registrar on the CTSU roster. Site and/or Data 
Administrators can manage CTSU roster roles via the new Site Roles maintenance feature 
under RSS on the CTSU members' web site. This will allow them to assign st aff the 
"Registrar" role.  
Note: The OPEN system will provide the site with a printable confirmation of registration and 
treatment information. Please print this confirmation for your records. 
Further instructional information is provided on the OPEN tab of  the CTSU members’ side of the 
CTSU website at https://www.ctsu.org or at https://open.ctsu.org . For any additional questions 
contact [CONTACT_25518] 1 -[PHONE_103] or [EMAIL_013] . 
Following registration, patients should begin protocol tre atment within 14 days.  Issues that would 
cause treatment holds should be discussed with the Study Chair.  
4.1 Phase I Patient Registration  
4.1.1 OPEN Registration Procedures  
This study is supported by [CONTACT_6818] (CTSU). 
Prior to the recruitment of a patient for this study, investigators must be registered mem bers 
of a Cooperative Group.  Each investigator must have an NCI investigator number and must 
maintain an “active” investigator registration status through the annual submission o f a 
Alliance A091101  
 
Version Date: 08/11/2017  27 Update #07  complete investigator registration packet (FDA Form 1572 with original signature, current 
CV, Supplemental Investigator Data Form with signature, and Financial Disclosure Form 
with original signature) to the Pharmaceutical Management Branch, CTEP, DCTD , NCI.  
These forms are available on the CTSU Web site ( enter credentials at https://www.ctsu.org; 
then click on the Register tab) or by [CONTACT_1340] [PHONE_4121] Monday through 
Friday between 8:30 a.m. and 4:[ADDRESS_1277811] obtain IRB approval for 
this protocol and submit IRB approval and supporting documentation to the CTSU 
Regulatory Office before they can enroll patients. Study centers can check the status of their 
registrat ion packets by [CONTACT_290546] (RSS) site registration 
status page of the CTSU member web site by [CONTACT_293590]://www.ctsu.org . 
Requirements for A091101  site registration:  
• CTSU IRB Certification  
• CTSU IRB/Regulator y Approval Transmittal Sheet 
• Study Chair approval 
Institutional Participation Requirements  
Institutions:  Institutions listed on the protocol cover page may participate in this study. 
Conference Calls : One representative from each participating institution must participate 
in a conference call every [ADDRESS_1277812]  participate in this call.  Institutions not participating in this 
conference call may be denied future registration to this study. A representative from CTEP may also take part in these calls.  
Dose Level Confirmation : During the Phase I portion of the trial, patient enrollment will 
be facilitated using the CTSU Sl ot Reservation  System in conjunction with the Oncology 
Patient Enrollment Network (OPEN). Prior to discussing protocol entry with prospective 
patients , site staff must use the CTSU OPEN Slot Reservation System to ensure that a slot 
for the study is available to the patient. Once a slot reservation confirmation is obtained, site 
staff may then proceed to enroll patients to this study. Please note that a slot reservation will only be held for up to seven calendar days. After [ADDRESS_1277813] been met, and the study site is listed as ‘approved’ in the CTSU RSS.  Patients  
must have signed and dated all applicable consents and authorization forms.   
All site staff  will use OPEN to enroll patients to this study.   OPEN can be accessed at 
https://open.ctsu.org or from the OPEN tab on the CTSU members’ side of the website at 
https://www.ctsu.org . 
Prior to accessing OPEN site staff should verify the following : 
• All eligibility criteria has been met within the protocol stated timeframes.  Site staff 
should use the  registration forms provided on the group or CTSU web site as a tool  
to verify eligibility.  
• All patients have signed an appropriate consent form and HIPAA authorization form  (if applicable).   
Alliance A091101  
 
Version Date: 08/11/2017  28 Update #07  Access requirements for OPEN:  
• Site staff will need to be registered with CTEP and have a valid and active CTEP -
IAM account. This is the same account (user id and password) used for the CTSU 
members' web site.  
• To perform registrations, the site user must have been assigned the 'Registrar' role 
on the relevant Group or CTSU roster.  
• To perform registrations on protocols for which you are a member of the Lead 
Group, you must have an equivalent 'Registrar' role on the Lead Group roster.  Role 
assignments are handled through the Groups in which you are a member  
• To perform registrations to trials accessed via the CTSU mechanism (i .e., non- Lead 
Group registrations) you must have the role of Registrar on the CTSU roster. Site and/or Data Administrators can manage CTSU roster roles via the new Site Roles 
maintenance feature under RSS on the CTSU members' web site. This will allow them to assign staff the "Registrar" role.  
Note : The OPEN  system will provide the site with a printable confirmation of registrati on 
and treatment information. Please print this confirmation for your records.  
Further instructional information is  provided on the OPEN tab of the CTSU members’ side 
of the CTSU website at https://www.ctsu.org  or at https://open.ctsu.org. For any additional 
questions contact [CONTACT_25518] 1 -[PHONE_103] or [EMAIL_013] . 
4.[ADDRESS_1277814] been met, and the study site is listed as ‘approved’ in the CTSU RSS.  Patients 
must have signed and dated the applicable consent .   
All site staff  will use OPEN to enroll patients to this study.   OPEN can be accessed at 
https://open.ctsu.org or from the OPEN tab on the CTSU members’ side of the website at https://www.ctsu.org . 
Prior to accessing OPEN site staff should verify the following : 
• All eligib ility criteria has been met within the protocol stated timeframes.  Site staff 
should use the  registration forms provided on the group or CTSU web site as a tool 
to verify eligibility.  
• All patients have signed an appropriate consent form and HIPAA 
authori zation  form  (if applicable).   
Access requirements for OPEN : 
• Site staff will need to be registered with CTEP and have a valid and active CTEP -
IAM account. This is the same account (user id and password) used for the CTSU 
members' web site.  
• To perform registrations, the site user must have been assigned the 'Registrar' role on the relevant Group or CTSU roster.  
• To perform registrations on protocols for which you are a member of the Lead Group, you must have an equivalent 'Registrar' role on the Lead Group roster.  Role 
assignments are handled through the Groups in which you are a member  
• To perform registrations to trials accessed via the CTSU mechanism (i.e., non -
Lead Group registrations) you must have the role of Registrar on the CTSU r oster. 
Site and/or Data Administrators can manage CTSU roster roles via the new Site 
Alliance A091101  
 
Version Date: 08/11/2017  29 Update #07  Roles maintenance feature under RSS on the CTSU members' web site. This will 
allow them to assign staff the "Registrar" role.  
Note:   The OPEN  system will provide the site  with a printable confirmation of registration 
and treatment information.   Please print this confirmation for your records.   
Further instructional information is  provided on the OPEN tab of the CTSU members’ side 
of the CTSU website at https://www.ctsu.or g or at https://open.ctsu.org. For any additional 
questions contact [CONTACT_25518] 1 -888-823- 5923 or [EMAIL_013] . 
4.3 Stratification  Factors 
Randomization will be stratified by:  
1) Tumor nodal status: 
• T1-3, N0- N2a versus  
• N2b, N2c- N3 and /or T4  
2) Oropharyngeal disease/ HPV status:  
• non-oropharyngeal disease versus  
• oropharyngeal disease w ith HPV pos itive status versus   
• oropharyngeal disease w ith HPV neg ative status  
3) Institution  
* Note: stratification by [CONTACT_910213] s tratifies by [CONTACT_910214], as it is planned that 
concomitant CRT will be an institution -level choice.   
5.0 TREATMENT  PLAN 
Study Overview  
Phase I portion : This will be a dose- escalation scheme to determine the MTD of ABT -888. Induction 
chemotherapy will be followed by [CONTACT_127958] 2 options of concomitant chemoradiotherapy, as described in Section 5.1.2.  
Phase II portion : Patients will be randomized in a 1:1 manner to receive induction chemotherapy 
with or without  ABT -888 at the dose determined during Phase I. Randomization will be stratified by 
[CONTACT_20150]/nodal status (T1- 3, N0- N2a versus N2b -N3 and/or T4), oropharyngeal disease/ HPV status  and 
institution (and implicit ly, institutional- chosen concomitant CRT) as descr ibed in Section 2.5. 
Induction chemotherapy will be followed by [CONTACT_127958] 2 options of concomitant chemoradiotherapy, as described in Section 5.1.2. Treatment assignment will be double -blinded. Induction c hemotherapy 
will be administered on an outpatient basis . Exceptions can be made if patients need hospi[INVESTIGATOR_910191], which should not delay treatment. Chemoradiotherapy can be administered on an 
inpatient or outpatient basis.  Expected AEs and appropriate dose modifications for carboplatin , 
paclitaxel and 5 -fluorouracil, hydroxyurea, and radiation are described below. No investigational or 
commercial agents or therapi[INVESTIGATOR_319522]'s malignancy.  
5.1 Phase I  
5.1.1 Induction Chemotherapy  
There will be 2, three -week cycles (6 weeks total) in the induction chemotherapy portion of 
Phase I.  ABT -[ADDRESS_1277815] 7 days of Cycle 1 and 2  
(starting on Day 1). This will be combined with a chemotherapy regimen of carboplatin and 
Alliance A091101  
 
Version Date: 08/11/2017  30 Update #07  paclitaxel . Carboplatin will be administered on Day 1 of each 21 day cycle and paclitaxel 
will be administered on Days 1, 8, and 15 of each 21 day cycle. 
This will be a dose -escalation scheme to determine the MTD of ABT -888. Patients will be 
placed in one of the dose  cohort s of ABT -888 listed below, using a conventional 3+[ADDRESS_1277816] cycle will be used to determine dose lev el. Two 3- week cycles of induction 
chemotherapy will be followed by [CONTACT_910215].
Allia nce A091101  
Version Date: 08/11/2017  31  Update #07   
Dose Levels  
ABT -888 doses will be given at  200 mg bid for 7 days in combination with paclitaxel 100 
mg/m2 and carboplatin AUC 6. Plea se see the table below for dose cohorts that are planned 
for the study design. 
Dose Cohort  ABT -888 Paclitaxel  
(weekly)  Carboplatin   
(every 3 weeks)  
-3 50 mg BID x 7 days  100 mg/m2  6 AUC  
- 2 100 mg BID x 7 days  100 mg/m2 6 AUC  
-1 150 mg BID x 7 days  100 mg/m2 6 AUC  
*0B 200 mg BID x 7 days  100 mg/m2 6 AUC  
1 250 mg BID x 7 days  100 mg/m2 6 AUC  
2 300 mg BID x 7 days  100 mg/m2 6 AUC  
3 350 mg BID x 7 days  100 mg/m2 6 AUC  
* starting dose 
Drugs are given sequentially; start next drug after completion of previous one.  
ABT -888 PO twice daily on days 1-7, every three weeks for 2 cycles.  Dose according to 
assigned cohort .  
Paclitaxel: 100 mg/m2 IV infusion (on Day 1) , every week on days 1, 8,  and 15 for 2 cycles, 
followed by…. 
Carboplatin : AUC 6, every 3 weeks for 2 cycles.  Carboplatin will be administered as an 
intravenous infusion over 30 minutes. The carboplatin dose will be calculated using 
the Calvert formula using AUC of 6 as follows:  
Carboplatin dose in mg* = 6 X (GFR + 25)  
* Calculated total dose is in mg, not mg/m2 
The Creatinine Clearance (to replace GFR) will be calculated for each treatment 
course using the formula: 
CrCl = (140 - age ) X weight in kg. X (0.85 only if female)  
            72 X serum creatinine 
Note: The GFR (calculated by [CONTACT_3158] -Gault ) used in the Calvert  formula to 
calculate AUC -based dosing should not exceed 125 mL/min (i.e., maximum 
carboplatin dose is 900mg). 
At this time, there is no data for ABT -888 administration through PEG -tube.  Therefore, 
patients who are unable to swallow capsules at baseline need to be excluded.  Patients who 
develop dysphagia during treatment may not be able to complete the planned doses of ABT -
888.  Given the plan is to give this induction regimen for 2 cycles and 7 days of ABT -888, 
a significant number of missed doses of ABT -888 due to dysphagia is not expected. 
Nevertheless, if patients missed planned doses during cycle 1 of the phase I trial, they will be replaced. If they miss do ses during cycle 2, they will not be given later doses, and the 
patients will not be replaced during the phase I portion of this study.  
[IP_ADDRESS] Definition of Dose -Limiting Toxicity – Phase 1   
Alliance A091101  
 
Version Date: 08/11/2017  32 Update #[ADDRESS_1277817] cycle of induction 
chemotherapy. 
Dose Limiting Toxicity (DLT)  will be defined as follows, during the first cycle of induction 
chemotherapy: 
• Hematological toxicities:  
- Grade 4 neutropenia (ANC < 500) lasting more than 14 days  
- Febrile  neutropenia  
- Grade 4 thrombocytopenia  
- Dose delay of greater than 3 weeks due to failure to recover counts.  
• Non-hematological toxicities:  
- Study treatment -related grade 3 or grade 4 non- hematological toxicity 
(excluding alopecia, fatigue, hypersensitivity reaction, nausea, vomiting, 
constipation, diarrhea, hypokalemia, hypomagnesemia, hypocalcemia, 
hypophosphatemia, and grade 3 hypertension). 
- Dose delay of greater than 3 weeks for non -hematological toxicity despi[INVESTIGATOR_910192], maximum treatment for  diarrhea, nausea, 
vomiting, and hypertension. 
• Any drug- related death.  
Management and dose modifications associated with the above adverse events are outlined 
in Section 6.0. 
[IP_ADDRESS]  Dose Escalation  
Dose escalation will proceed  according to the following scheme.  
 
Number of Patients with DLT at 
a Given Dose Level Escalation Decision Rule  
0 out of 3  Enter 3 patients at the next dose level.  
>2 Dose escalation will be stopped.  This dose level will 
be declared the maximally administered dose (highest 
dose administered).  Three (3) additional patients will 
be entered at the next lowest dose level if only [ADDRESS_1277818] 3 more patients at this dose level.  
• If 0 of these 3 patients experience DLT, proceed to 
the next dose level.  
•  If 1 or more of this group suffer DLT, then dose 
escalation is stopped, and this dose is declared the 
maximally administered dose.   
•  Three (3) additional patients will be entered at the  
next lowest dose level if only 3 patients were treated 
previously at that dose.  
<[ADDRESS_1277819] be entered at the recommended  
phase 2 dose.  
Alliance A091101  
 
Version Date: 08/11/2017  33 Update #07  5.1.2 Concomitant Chemoradiotherapy Regimen Options  
Following induction chemotherapy, patients will be placed into one of 2 regimens of 
radiation and chemotherapy, based on the guidelines of the institution where they are being 
treated.  It is expected that the institutional choice of concomitant CRT will apply to all 
patien ts enrolled at that institution.  
OPTION 1: Concomitant Chemoradiotherapy with Cisplatin  
[IP_ADDRESS] Cisplatin Treatment during concurrent cisplatin/radiation treatment  
Cisplatin , 100 mg/m2, IV on days 1 and 22 (cisplatin  may be given  within  24 hours of 
days 1 and 22). 
Adjustment for actual or ideal body weight is per institutional standard.  
High  dose cisplatin  is a highly emetogenic regimen  with significant  incidence of delayed 
nausea and  vomiting.  Institutional guidelines for highly emetogenic regimens should be 
followed. In the absence of such guidelines, see Section 5.3. 
Hydration and diuresis : per institutional guidelines.  
[IP_ADDRESS] Dose Specifications for 3D Radiotherapy  during concurrent cisplatin/radiation 
treatment  
The initial target volume encompassing the gross and subclinical disease sites will receive 
1.[ADDRESS_1277820] 
volume covering gross tumor and clinically/radiologically involved nodes will receive boost 
irradiation of 1.5 Gy/Fx delivered as a second daily fraction (with at least a six -hour interval) 
for a total of 12 treatment days (18 Gy total). The boost irradiation should commence during 
week [ADDRESS_1277821] at 32.4 Gy/18 Fx of the initial target volume 
(i.e., latter part of week 4). All treatment times must be documented on the treatment record. 
The primary tumor and cli nically/radiologically -involved nodes (PTVHD) will thus receive 
72 Gy in 42 fractions over 6 weeks, and uninvolved upper neck nodes (PTVED) will receive an elective dose of 54 Gy in 6 weeks.  
When desired, PTVINT can receive a total dose of 63 Gy, i.e., by  [CONTACT_26129] 9 fractions of 
1.5 Gy to PTVINT before making a second cone down to PTVHD. Clinically/radiologically 
negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. 
The uninvolved lower neck nodes will receive 1.8 Gy per fraction at 3- cm depth to a total 
dose of 50.4 Gy in 28 fractions in 5.6 weeks through a matching AP or AP/PA lower neck 
field. Involved lower neck nodes can receive a total dose of up to 69 -72 Gy when it is 
possible to limit the dose to the brachial plexus to ≤ 60 Gy. If this is not possible, the total 
dose can be limited to 60 Gy, in which case, neck dissection is mandatory regardless of the response.  
Technical Factors 
• Photon beams of ≥4 MV and/or electron beams from 6-25 MeV are required. 
• Treatment distance must be ≥ [ADDRESS_1277822] scan  
Alliance A091101  
 
Version Date: 08/11/2017  34 Update #[ADDRESS_1277823] scan.  
Treatment Planning/Target Volumes  
• CT based treatment planning is mandatory for every patient.   
• Gross Tumor Volume (GTV) represents the region judged to contain gross primary 
tumor or involved node(s) based on clinical and endoscopic examinations, CT scan, and, when applicable, other imaging techniques.  Grossly positive lymph nodes are 
defined as any lymph nodes > 1 cm or nodes with a necrotic center. 
• Clinical Target Volume (CTV) is defined as the GTV plus areas considered at risk 
for containing microscopic disease delineated by [CONTACT_1963].  CTV1 
represents GTV plus a margin of generally 1 cm and CTV2 represents GTV with a 
margin of about 2 cm and n odal regions to receive elective irradiation.  When the tumor 
is infiltrative (endophytic) or when the border is ill defined, it might be desirable to deliver an intermediate dose (e.g., 59- 63 Gy) to a volume (CTVINT) that is slightly 
larger than CTV1.  Th e CTV margins can be narrower when GTV is in the proximity 
of the spi[INVESTIGATOR_453696].  
• Planning Target Volume  (PTVHD  and PTVED) represents an additional margin 
around CTV1 and CTV2 to compensate for the variability of treatment set up  and 
internal organ motion. A minimum margin of 0.[ADDRESS_1277824] or other critical normal tissues. In such situations, the m argin 
can be reduced judiciously. A minimum margin of 3 mm can be used in all directions as long as an institution implements a study to define the appropriate magnitude of the 
uncertain components of the PTV. Careful consideration should be made when defi ning 
the superior and inferior margins in three dimensions.  
• The density corrected dose distributions shall be calculated and the dose 
prescription is to be based on a dose distribution corrected for heterogeneities. 
Critical Structures  
• Spi[INVESTIGATOR_1831]:  A margin of 0.[ADDRESS_1277825] may be added to create 
a Planning Organ at Risk Volume (PRV).  The dose to any point within the spi[INVESTIGATOR_399016] 48 Gy to any volume larger than 0.03 cc (approximately equivalent 
to a 3x3x3 mm cube). 
• Glottic larynx: In patients with oropharyngeal carcinoma without extension to the 
larynx, placing the isocenter just above the arytenoids and irradiating the lower neck 
with an anterior matching field with larynx block can minimize the dose to the glottic 
larynx.  Alternatively, the dose to the larynx should be kept <45 Gy whenever feasible. 
• Brachial plexus:  The dose to the brachial plexus must be limited to ≤ 60 Gy in 
patients with level IV node(s).  
• Unspecified tissue outside the target volumes: ≤ 100 % of the dose prescribed to 
CTV1. No more than 5% of the non- target tissue can receive greater than the dose to 
CTV1.  
Compliance Criteria  
Alliance A091101  
 
Version Date: 08/11/2017  35 Update #07  • Treatment breaks must be clearly indicated in the treatment record along with the 
reason(s) for the treatment  break( s). Missed treatments due t o holidays or logistic 
reasons can be  compensated for by [CONTACT_910216] a 
minimum interfraction interval of 6 hours.  
• Treatment breaks should be allowed only for resolution of severe acute toxicity 
and/or for intercurrent illness and ideally, should not exceed 5 treatment days at a time 
and 10 treatment days in total. Any treatment break(s) exceeding two treatment days 
for reasons other than toxicity/illness will be considered a protocol deviation.  
• Plan normalization should provide coverage of 95% of the volume of the PTV of 
the GTV (PTVHD) with the prescribed dose of 69.96 Gy.   No more than 1% of the 
volume of the PTVHD should receive less than 64 Gy.  Additionally, no more than 
20% of the PTV of  the GTV should receive more than 76 Gy, and no more than 5% of 
this volume should receive more than 79 Gy.  These numbers describe the DVH shown 
in the figure below with the diamond shaped symbols. Obviously, better DVHs (i.e., 
with smaller amounts of eit her underdose or overdose) are preferable.  
• A region of “minor deviation” is also defined in the figure as the DVH represented 
by [CONTACT_910217].  Deviations of this magnitude are not desirable, but will be 
deemed acceptable. That is, a DVH with at least 97% of the volume receiving 64 Gy 
is acceptable as a minor deviation. Additionally, as a minor deviation for the overdose 
region, as much as 40% of the PTVHD   volume can receive 76 Gy and up to 20% of 
this volume can receive 79 Gy.  DVHs for the PTVHD  falling outside the limits for a 
minor deviation (i.e., increased under or overdose) will be scored as unacceptable 
“major deviations.” 
• The DVHs for the other target regions should deliver the prescribed dose, as much 
as possible, to at least 95% of the  volume of that PTV. 
 
Overall  
Evaluation  Radiotherap
y 
Prolongation
 Total  Dose  
Variation 3- D RT  Total Dose Variation  
IMRT**  
Per Protocol  ≤ 5 days  ≤ 4% deviation  from  
prescribed dose See parameters in the figure and  
table below  
Minor Variation  
(Acceptable)  6-10 days  > 4% to ≤ 9%  See parameters in the figure and  
table below  
Major Deviation  
(Unacceptable)  > 10 days  > 9% Deviat ions greater than presented  
in the figure/table below  
*These  criteria  are to be reassessed  based  on the results  of the recently  completed  RTOG  trial, 
0129. 
**Note: For IMRT, prescription dose is the isodose surface that encompasses at least 95% 
of the planning  target  volume (PTV)  with no more  than 20% of any PTV HD receiving ≥ 
Alliance A091101  
 
Version Date: 08/11/2017  36 Update #07  110% of the prescribed  dose and no more  than 1% of any PTV HD and PTVED receiving ≤ 
93% of the prescribed dose. 
 
 
 
 
Dose (Gy)   
Per Prescription   
Minor variation  
65 99% 97% 
70 95% 95% 
77 20% 40% 
80 5% 20% 
OPTION 2: Concomitant Chemoradiotherapy with TFHX  
[IP_ADDRESS] Chemotherapy should be administered during all 5 weeks of radiotherapy.  If less than 3 
days of radiation therapy (RT) are required during Week 5, chemotherapy may be omitted.  
Repeat every 14 days for a total of 5 cycles.  
P.M.:   hydroxyurea  [ADDRESS_1277826] fraction of daily radiotherapy. 
6:00 P.M .: 5-FU 600 mg/m2 /day IV infusion over 120 hours beginning the evening before 
radiotherapy star ts.  Total dose 3000mg/m2 per cycle. (5-FU may begin in the morning  prior 
to the first daily radiotherapy fraction)  
Paclitaxel  100 mg/m2 IV infusion on the first day of radiotherapy.  Premedication  for 
paclitaxel according to institutional procedures. 
Radi ation therapy  is administered twice daily for 5 days (Mon - Fri) at 150 cGy per 
fraction. 
Chemoradiotherapy cycles are repeated every 14 days until the completion of radiotherapy.  
[IP_ADDRESS] Radiotherapy Guidelines for concurrent TFHX treatment  
1. All patients  will have a complete dental evaluation prior to the start of radiation 
therapy, ideally prior to the start of chemotherapy.  
2. Prior to the initiation of induction chemotherapy, all patients will be properly 
immobilized and simulated in the treatment position with a contrast enhanced CT scan for 
planning purposes.  Additionally, after the completion of induction chemotherapy and prior 
to the initiation of concurrent chemoradiotherapy, all patients will undergo a second 
planning CT scan.  The pre - and post- chemotherapy scans will be fused to define the targets 
below. Slice thickness for all planning CT scans should optimally be 3mm and no greater 
than 5 mm. 
3. Target volume definition:  Three volumes will be defined on each planning CT 
slice where appropriate.  Gross disease based on all available imaging and clinical 
information will be designated as gross tumor volume (GTV).  Planning target volume 1 
(PTV1) will include the GTV + a 1.5 cm margin for set -up uncertainty, organ motion, and 
microscopic extension.  High risk microscopic disease (PTV2) will include the entirety of PTV1 and will also include the nodal stations at risk for microscopic spread.   
Alliance A091101  
 
Version Date: 08/11/2017  37 Update #07  • Contouring the primary and involved neck nodes (GTV) will be performed per 
consensus recommendations [Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, 
Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS.  Clinical Practice Guidance 
for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced 
Head -and- Neck Cancer.  Int J Radiat Oncol Biol Phys . 2009 Apr 11.] In general, the pre -
induction chemotherapy scan is used to define the primary tumor GTV and the post -
induction chemotherapy volume is used to define the nodal volume GTV. 
• PTV1 will be created by [CONTACT_910218] 1.5 cm.   
• PTV2 will include all of PTV1 as well as the next regional nodal not involved with 
pathologic lymphadenopathy.  Anatomic guidelines for lymph node stations will be 
defined using the RTOG Head and Neck Atlas Guidelines for delineation of the Nodal 
CTV.   
Additionally site by [CONTACT_910219]. 
i.  Guidelines for definition of PTV2: 
• PTV2 is defined as the entirety of PTV1 as well as the next nodal station at risk.  
• For example, a patient have an ipsilateral level 2 LN involved as GTV, PTV2 will 
encompass ipsilateral level 3.  
• PTV2 may not differ significantly from PTV1 if the required GTV expansion 
includes the next nodal station at risk. 
• For tumors that cross midline in the oral cavity or oropharynx, PTV [ADDRESS_1277827].  An example would be a soft palate tumor or a base of tongue 
tumor that crosses midline.   
• PTV1 and PTV2, can be modified at the discretion of the treating physician for the 
constraints of normal tissue tolerance and to avoid extension beyond the skin.  Variations 
in anatomy and tumor size make it necessary for the radiation oncologist to carefully 
define the PTV on each individual CT slice.  Reasonable attempts should be made to 
provide an adequate treatment volume without encroaching on critical organs (e.g. spi[INVESTIGATOR_36232]) or extending to the skin. 
4. Radiotherapy Techniques Allowed: Either 3- D CT based treatment planning or 
Intensity Modulated Radiation Treatment (IMRT) techniques will be acceptable.  
• Planning Goals:  In  both instances the physician will attempt to deliver an even 
dose to the target tissue and minimize doses to surrounding normal structures.  
• Blocking will be individualized for each patient.  Either custom Cerrobend blocks 
or mutileaf collimation will b e acceptable.  
• Field Size: Appropriate field sizes will be determined at the time of simulation to 
treat gross disease and areas of potential microscopic disease.  Initial field size and 
arrangement will be at the discretion of the attending radiation onc ologist.  The optimal 
field arrangement will be determined based on the treatment planning techniques employed.  All fields must be treated during each treatment session.  
5. 3D Conformal technique and prescription: 
i. The neck should be treated with oppose d lateral fields using a half -field technique.   
ii. In general, the lower neck should be treated with an anterior field to a depth of 3 
cm.  Opposed fields for the lower neck are permitted in order to improve PTV coverage and 
increase homogeneity.   
Alliance A091101  
 
Version Date: 08/11/2017  38 Update #[ADDRESS_1277828] block would cover tumor. 
vii. Acceptable plans will encompass the PTV within the 95% isodose line.  
viii. The dose variation in the PTV will be +7% and -5% of the pre scription point dose.   
ix. Electron fields shall be prescribed to the depth of maximum dose with the energy 
and field size chosen so that the target volume is encompassed within 90% of the prescribed 
dose. 
6. IMRT technique and prescription 
i. Optimal IMRT planning will depend on the planning system employed.   
ii. We anticipate that the optimal plan will use 7 to 11 gantry positions.   
iii. Acceptable plans will encompass the PTV with the 95% isodose line.   
iv. No more than 1% of the PTV shoul d receive less than 1% of the prescribed dose.   
v. Plans should be reviewed to ensure that any part of the PTV getting less than 95% 
of the prescription dose is at the edge of the volume.   vi. In no situation should a central area of the PTV receive less than 95% of the 
prescribed dose.   
vii. No more than 1% of the PTV should receive 110% of the prescription dose.   
Radiation Dose : each cycle of treatment will consist of 5 consecutive days of 
hyperfractionated radiation with 150 cGy given bid with a 6 hour interval between radiation 
fractions (300 cGy per day and 1500 cGy per week) in conjunction with chemotherapy. 
i. The dose for PTV1 will be 70-[ADDRESS_1277829] dose to < [ADDRESS_1277830].  
Countouring Atlas for Head and Neck: 
http://www.rtog.org/atlases/hnatlas/tableneck.html 
Detailed Site by [CONTACT_374116] 2 Delineation: 
Base of Tongue:  Lateralized  
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 includes:              
Alliance A091101  
 
Version Date: 08/11/2017  39 Update #07  Ipsilateral  IB, II  IA, 
II IB, 
III II, 
IV II,III  II, 
III IA, IB, II  II II II II II 
Contralateral  IA II II II II II IB II IB II, 
IV II, 
III II, 
III 
 
Base of Tongue:  Crosses Midline  
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IB, 
III II, 
IV II,III  II, 
III IA, IB, II  II II II II II 
Contralateral  IA --- II II II II IB II IB, 
III II, 
IV II, 
III II, 
III 
 
Soft Palate:  
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  II IB, 
III II, 
IV II,III  II, 
III IA, IB, II  II II II II II 
Contralateral  IA II II II II II IB IA(?), 
II IB, 
III II, 
IV II, 
III II, 
III 
 
 Tonsil:  No BOT invasion  
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IB, 
III II, 
IV II,III  II, 
III IA, IB, II  II II II II II 
Contralateral  IA --- --- --- --- --- IB IA(?), 
II IB, 
III II, 
IV II, 
III II, 
III 
 
Tonsil:  BOT Invasion 
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
Alliance A091101  
 
Version Date: 08/11/2017  40 Update #07  PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IB, 
III II, 
IV II,III  II, III  IA, IB, II  II II II II II 
Contralateral  IA --- II II II II IB II IB, 
III II, 
IV II, 
III II, 
III 
 
Larynx: T1-2 
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II III II, 
IV II,III  II, 
III IA, IB, II  II II III III II 
Contralateral  IA --- II II II II IB II  III II, 
IV II, 
III II, 
III 
 
Larynx: T3-4 
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II IA, 
II III II, 
IV II,III  II, 
III IA, IB, II  II II III III II 
Contralateral  IA --- II II II II IB II  III II, 
IV II, 
III II, 
III 
 
Hypopharynx 
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  II, 
III,  III,IV  II, 
IV II,III  II, 
III,IV  IA, IB, II  II II III III II 
Contralateral  IA --- II, III  II, 
III II, III  II,III  IB II  
III II, 
IV II, 
III II, 
III 
 
Lower Gingiva  
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Alliance A091101  
 
Version Date: 08/11/2017  41 Update #07  Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IA, 
IB, 
III IA, 
IB,II, IV IB, 
IA, II,III  IA, 
IB, II, 
III IA, IB  IA 
,II IA, 
IB, II,  IA, 
IB, II IA, 
IB, II, IA, 
IB, II, 
Contralateral  IA, IB  --- --- --- --- --- IB, II  IA, 
II  IA, 
IB, III IB, 
IA, II, IV IA, 
IB, II, II, 
III II, 
III 
 
Retromolar Trigone  
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IB, 
III IB,II, 
IV IB, 
II,III  IB, 
II, 
III IA, IB  IA 
,II IB, 
II,  , IB, 
II IB, 
II, IB, 
II, 
Contralateral  IA, IB  --- --- --- --- --- IB, II  IA, 
II  IB, 
III IB, 
II, IV IB, 
II, II, 
III II, 
III 
 
Oral Tongue:  Lateralized  
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IA, 
IB, 
III IA, 
IB,II, IV IB, 
IA, II,III  IA, 
IB, 
II, 
III IA, IB, II  IA 
,II IA, 
IB, II,  IA, 
IB, II IA, 
IB, II, IA, 
IB, II, 
Contralateral  IA, IB  --- --- --- --- --- IB, II  IA, 
II  IA, 
IB, 
III IB, 
IA, II, IV IA, 
IB, II, II, 
III II, 
III 
 
Oral Tongue:  Crosses Midline  
 Adenopathy 
Level             
Alliance A091101  
 
Version Date: 08/11/2017  42 Update #[ADDRESS_1277831]. Daniel Haraf [(773) 702 -
5976, [EMAIL_17354]].  
Missed treatments due to holidays or logistical reasons can be compensated for by [CONTACT_910220] a minimum interfraction interval of 6 hours or by [CONTACT_910221] a Saturday or Sunday. 
5.1.3  Duration of Follow up  
See Section 5.5 for clinical and survival follow -up schedule.  
5.2 Phase II 
Patients will be randomized in a 1:1 manner to receive induction chemotherapy with or without  
ABT -888 at the dose determined during Phase I. Within 10 days after the completion of 
induction chemotherapy (i.e., week 6, day 7) patients will begin  one of 2 options of concomitant 
chemoradiotherapy ( as described in Section 5.1.2 ). It is expected that the institutional choice of 
concomitant CRT will apply to all patients enrolled at that institution. Treatment assignment 
will be double -blinded.  
5.2.1 Carboplatin -Paclitaxel Induction Chemotherapy -Repeat every 3 weeks for 2 cycles   Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IA, 
IB, 
III IA, 
IB,II, IV IB, 
IA, II,III  IA, 
IB, II, 
III IA, IB, II  IA 
,II IA, 
IB, II,  IA, 
IB, II IA, 
IB, II, IA, 
IB, II, 
Contralateral  IA, IB  IA, 
IB IA, 
IB IA, 
IB IA, 
IB --- IB, II  IA, 
II  
IA, IB, III IB, 
IA, II, IV IA, 
IB, II, II, 
III II, 
III 
 Adenopathy 
Level             
 Ipsilateral       Contralateral       
Involved 
nodes:  IA IB II III IV V IA IB II III IV V 
PTV 2 
includes:              
Ipsilateral  IB, II  IA, 
II IA, 
IB, III IA, 
IB,II, IV IB, 
IA, II,III  IA, 
IB, II, 
III IA, IB, II  IA 
,II IA, 
IB, II,  IA, 
IB, II IA, 
IB, II, IA, 
IB, II, 
Contralateral  IA, IB  IA, 
IB IA, 
IB IA, 
IB IA, 
IB --- IB, II IA, 
II  
IA, IB, III IB, 
IA, II, IV IA, 
IB, II, II, 
III II, 
III 
Alliance A091101  
 
Version Date: 08/11/2017  43 Update #07  The doses of carboplatin and paclitaxel  will remain the same during the phase I and II 
induction chemotherapy (refer to Section 5.1.1) Dose delays and dose modifications should 
take place as described below. The total duration of i nduction chemotherapy should be 
6 weeks and not exceed 8 weeks.  
 ABT -888/placebo Twice daily at the dose determined in phase I, on days 1-7 ( for a 
total of 7 days and 14 doses). 
Paclitaxel: 100 mg/m2 IV infusion over 60 minutes on Days 1, 8, and 15 
Carboplatin: AUC 6, every 3 weeks for 2 cycles. Carboplatin will be administered as an 
intravenous infusion over 30 minutes. The carboplatin dose will be calculated using 
the Calvert formula using AUC of 6 as follows:  
Carboplatin dose in mg* = 6 X (GFR + 2 5)  
* Calculated total dose is in mg, not mg/m2 
The Creatinine Clearance (to replace GFR) will be calculated for each treatment course using the formula: 
CrCl = (140 - age ) X weight in kg. X (0.85 only if femail)  
            72 X serum creatinine 
Note: Th e GF R (calculated by [CONTACT_3158] -Gaul ) used in the Calvert formula to 
calculate AUC -based dosing should not exceed 125 mL/min (i.e., maximum 
carboplatin does is 900mg). 
5.2.2 Concomitant Chemoradiotherapy 
Concomitant chemoradiotherapy will start within 10 days  from the completion of cycle 2 
of carboplatin -pactlitaxel i nduction chemotherapy  (as the cycles are 21 days long, patients 
should start concomitant therapy by [CONTACT_4475] 31 of cycle 2) . It is expected that the institutional 
choice of concomitant CRT will app ly to all patients enrolled at that institution.  
OPTION 1:  Concomitant Chemoradiotherapy with Cisplatin  as described in Cisplatin , 
100 mg/m2, IV on days 1 and 22 (cisplatin  may be given  within  24 hours of days 2 and 
23). 
Adjustments for actual or ideal body weight is per institutional standard.   
High  dose cisplatin  is a highly emetogenic regimen  with significant incidence of 
delayed nausea and  vomiting.  Institutional guidelines for highly emetogenic regimens 
should be followed.  In the absence of such guidelines, see Section 5.3.  
Hydration and diuresis : per institutional guidelines .  
For dose specifications for 3D Radiotherapy refer to Section [IP_ADDRESS]. 
OR 
OPTION 2: Concomitant Chemoradiotherapy with TFHX   
Chemotherapy should be administered during all 5 weeks of radiotherapy.  If less than 3 
days of radiation therapy (RT) are required during Week 5, chemotherapy may be 
omitted. Repeat every 14 days for a total of 5 cycles.  
P.M.:  hydroxyurea [ADDRESS_1277832] fraction of daily radiotherapy. 
Alliance A091101  
 
Version Date: 08/11/2017  44 Update #07  6:00 P.M.: 5- FU 600 mg/m2/ day IV infusion over 120 hours beginning the evening 
before radiotherapy starts.  Total dose 3000mg/m2 per cycle. ([ADDRESS_1277833] daily radiotherapy fraction) 
Paclitaxel 100 mg/m2 IV infusion on the first day of radiotherapy. Premedication for 
paclitaxel according to institutional procedures. 
Radiation therapy is administered twice daily for 5 days (Mon- Fri) at 150 cGy per 
fraction. 
Chemoradiotherapy cycles are repeated every 14 days until the completion of 
radio therapy.  
For dose specifications for 3D Radiotherapy refer to Section [IP_ADDRESS]. 
5.3 Concomitant Medication and Supportive Care Guidelines  
5.3.1 S upportive care  for Carboplatin-Paclitaxel Induction 
Pre-medications, hydration, and a ntiemetics  should be given according to institutional 
procedures. 
• Breakthrough  nausea and vomiting  and delayed nausea and vomiting should be 
managed  aggressively according to institutional procedures.  
• Colony stimulating factors should be given as described in Section 6.0. 
5.4 Duration of Therapy  
The total duration of induction chemotherapy should be 6 weeks, and not exceed 8 weeks. In no 
case should the duration of induction chemotherapy exceed 8 weeks or 2 cycles. In the absence 
of treatment delays due to adverse event(s), treatment may continue for 2 cycles or until one of 
the following criteria applies:  
Disease progression,  
Unacceptable adverse event(s),  
Patient decides to withdraw from the study, or General or specific changes in the patient's condition render the patient unacceptable for further 
treatment in the judgment of the investigator.  
5.5 Duration of Follow Up   
5.5.1 Clinical Follow- Up  
Medical Oncology and/or Radiati on Oncology: A brief history and physical by a medical 
oncologist and/or radiation oncologist must be done at 2 weeks, 1 month and 3 months from 
the end of chemoradiotherapy treatment, then  every 3 months through year 2, every 6 
months in year 3 and annually in years 4 and 5. 
ENT or Head and Neck Surgeon : An examination by [CONTACT_743999], 
including laryngopharyngoscopy (mirror and/o r fiberoptic and/or direct procedure), must be 
completed at months 1 and 3 from the end of chemoradiotherapy treatment, then every 3 
months through year 2, every 6 months in year 3, and annually in years 4 and 5. Imaging: 3, 6, 12, 18, 24, 30, 36, 48, and 60 months following the end of CRT, any of the 
following options: a) CT scan of the neck (with contrast)  and a chest CT scan (with or 
without contrast); b) MRI of the neck and a chest CT scan (with or without contrast); c) CT 
scan of the neck and a PET/CT of neck and chest (with or without contrast).  
Alliance A091101  
 
Version Date: 08/11/2017  45 Update #[ADDRESS_1277834] progressed  will be followed every 6 months through year 5.   
5.6 Criteria for Removal from Study  
Patients will be removed from study treatment when any of the criteria listed in Section 5.4  
applies.  
Alliance A091101  
 
Version Date: 08/11/2017  46 Update #07  6.0 DOSE  MODIFICATIONS  FOR  PHASE  I ONLY 
Please note, the dose modifications for the phase II portion will be determined once the dose of ABT -
888 is known for the phase II portion. When we reach the phase II portion, an amendment will detail 
the new dose modifications. 
General rules for dose modi fication:  
• If multiple adverse events are seen, administer dose based on greatest reduction required for 
any single adverse event observed.   
• Reductions apply to treatment given in the preceding cycle and are based on adverse events 
observed since the prior dose.  
• Paclitaxel will not be re -escalated once reduced  
• If dose reductions beyond dose level -1 is required induction will be discontinued, and patient 
will move to concurrent chemoradiotherapy  
• If treatment is held 21 days or more, patient will move on to concurrent chemoradiotherapy  
• CTEP -AERS reporting may be required for some adverse events (See Section  7.0) 
Growth Factors:  
In general, patients will NOT receive prophylactic filgrastim (G -CSF), tbo -filgrastim,  PEG -
filgrastim (Neulasta), or sargramostim (GM -CSF) unless they experience treatment delays, dose 
omissions, or recurrent neutropenic complications after treatment modifications as specified. In 
particular, hematopoietic growth factors should not be used to avoid initial chemotherapy dose modifications as stipulated in the protocol. However, patients may also receive growth factors 
for management of neutropenic complications in accordance with clinical treatment guidelines.  
When GCSF is utilized, given the weekly chemotherapy doses, it is recommended that filgrastim, 
tbo-filgrastim or sargramostim (dosed according to institutional standard) will be administered 
daily subcutaneously starting [ADDRESS_1277835] dose of weekly paclitaxel. 
As a reminder, dose cohorts for th e phase I trial are:  
Dose Cohort  ABT -888 Paclitaxel  
(weekly)  Carboplatin   
(every 3 weeks)  
-3 50 mg BID x 7 days  100 mg/m2  6 AUC  
- 2 100 mg BID x 7 days  100 mg/m2 6 AUC  
-1 150 mg BID x 7 days  100 mg/m2 6 AUC  
*0B 200 mg BID x 7 days  100 mg/m2 6 AUC  
1 250 mg BID x 7 days  100 mg/m2 6 AUC  
2 300 mg BID x 7 days  100 mg/m2 6 AUC  
3 350 mg BID x 7 days  100 mg/m2 6 AUC  
* starting dose 
6.1 Dose Reduction and Delays during Induction  
Dose modification tables for phase I induction by [CONTACT_9084] : 
Cohort 0B: 
Dose level  ABT -888 Carboplatin  Paclitaxel  
0 (starting dose)  200 mg bid x 7 days  6 AUC  100 mg/m2 
-1 150 mg bid x 7 days  5 AUC  80 mg/m2 
Alliance A091101  
 
Version Date: 08/11/2017  47 Update #07   
Cohort 1: 
Dose level  ABT -888 Carboplatin  Paclitaxel  
0 (starting dose)  250 mg bid x 7 days  6 AUC  100 mg/m2 
-1 200 mg bid x  7 days  5 AUC  80 mg/m2 
Cohort 2: 
Dose level  ABT -888 Carboplatin  Paclitaxel  
0 (starting dose)  300 mg bid x 7 days  6 AUC  100 mg/m2 
-1 250 mg bid x 7 days  5 AUC  80 mg/m2 
Cohort 3: 
Dose level  ABT -888 Carboplatin  Paclitaxel  
0 (starting dose)  350 mg bid x 7 days  6 AUC  100 mg/m2 
-1 300 mg bid x 7 days  5 AUC  80 mg/m2 
Cohort -1: 
Dose level  ABT -888 Carboplatin  Paclitaxel  
0 (starting dose)  150 mg bid x 7 days  6 AUC  100 mg/m2 
-1 100 mg bid x 7 days  5 AUC  80 mg/m2 
Cohort -2: 
Dose level  ABT -888 Carboplatin  Paclitaxel  
0 (starting dose)  100 mg bid x 7 days  6 AUC  100 mg/m2 
-1 50 mg bid x 7 days  5 AUC  80 mg/m2 
Cohort -3: 
Dose level  ABT -888 Carboplatin  Paclitaxel  
0 (starting dose)  50 mg bid x 7 days  6 AUC  100 mg/m2 
-1 Discontinue ABT -888 5 AUC  80 mg/m2 
6.1.1 Dose Modifications for Hematologic Toxicity During Induction  
For grade 2 neutropenia on day 1, proceed with carboplatin 1 dose level decreased, 
paclitaxel at same dose, and ABT -888 at same dose. For grade 3 or 4 neutropenia on day 1, 
delay da y 1 until grade ≤ 2, then proceed with carboplatin 1 dose level decreased, paclitaxel 
at same dose, and ABT-888 1 dose level decreased. For febrile neutropenia on day 1, delay day 1 until recovery, then proceed with carboplatin 1 dose level decreased, pacl itaxel at 
same dose, and ABT -888 1 dose level decreased.  
For grade 4 neutropenia on day 8, omit paclitaxel on day 8, and upon reaching day 1 proceed 
with carboplatin 1 dose level decreased, paclitaxel at same dose, and ABT -888 at same dose 
on day 1. For grade 4 neutropenia on day 15, omit paclitaxel on day 15, and upon reaching day 1 proceed with carboplatin 1 dose level decreased, paclitaxel at same dose, and ABT -
888 at same dose on day 1. 
For grade 1 thrombocytopenia on day 1, proceed with carboplatin at  1 dose level decreased, 
paclitaxel at same dose, and ABT -888 at same dose. For grade 2 thrombocytopenia on day 
1, delay day 1 until grade ≤ 1, then proceed with carboplatin 1 dose level decreased, 
paclitaxel at same dose, and ABT -888 at same dose. For grade 3 thrombocytopenia on day 
1, delay day 1 until grade ≤ 1, then proceed with carboplatin 1 dose level decreased, 
paclitaxel at same dose, and ABT -888 at 1 dose level decreased. For grade 4 
thrombocytopenia on day 1, delay day 1 until grade ≤ 1, then proc eed with carboplatin 1 
dose level decreased, paclitaxel 1 dose level decreased, and ABT -888 at 1 dose level 
decreased.  
Alliance A091101  
 
Version Date: 08/11/2017  48 Update #07  For grade 3 or 4 thrombocytopenia on day 8, omit paclitaxel on day 8, and upon reaching 
day 1 proceed with carboplatin 1 dose level decr eased , paclitaxel at same dose, and ABT -
888 at 1 dose level decreased on day 1. For grade 3 or 4 thrombocytopenia on day 15, omit paclitaxel on day 15, and upon reaching day 1 proceed with carboplatin 1 dose level decreased, paclitaxel at same dose, and A BT-888 at 1 dose level decreased on day 1. 
6.1.2 Dose Modifications for Neurotoxicity (CTCAE Nervous System Disorders) during 
Induction  
• For any grade seizure, discontinue ABT -888.  Continue carboplatin and paclitaxel  at 
same dose.  
• For grade 2 peripheral motor or sensory neuropathy, decrease paclitaxel  by [CONTACT_37387]. Continue carboplatin  and ABT-888 at the same dose.  
• For grade 3 or 4 peripheral motor or sensory neuropathy, delay all subsequent protocol -
directed therapy for a maximum of three weeks until grade ≤ 2 , then decrease paclitaxel  
and carboplatin  by [CONTACT_910222] -888 at the same dose.  
• If induction (cycle 2) is delayed for more than three  weeks, proceed to 
chemoradiotherapy. 
6.1.3 Musculoskeletal and Connective Tissue Toxicity During Induction  
• For grade 3 or 4 arthralgia, delay all subsequent protocol- directed therapy for a 
maximum of three weeks until  grade ≤ 2, then decrease paclitaxel  by [CONTACT_910223], and give carboplatin and ABT -888 at the same dose.  
• If Induction (cycle 2) is delayed for more than 2 weeks for arthralgia or myalgia, proceed 
to chemoradiotherapy. 
6.1.4 Fatigue (CTCAE General Disorders and Administration Site Conditions) during 
Induction  
• For grade 3 or 4 fatigue, delay all subsequent protocol -directed therapy for a maximum 
of three  weeks until grade  ≤ 2, then decrease paclitaxel  by [CONTACT_750054], and give carboplatin and ABT -888, at the same dose.  
• If Induction (cycle 2) is delayed for more than three  weeks for fatigue, proceed to 
chemoradiotherapy. 
6.1.5 GI Toxicity During Induction  
• For grade 2 mucositis, oral, decrease paclitaxel  by [CONTACT_649198], and 
give carboplatin and ABT -888 at the same dose. 
 • For grade 3 or 4 mucositis, oral, delay all subsequent protocol -directed therapy for a 
maximum of three weeks until grade ≤ 2 , then decrease paclitaxel and carboplatin by 
[CONTACT_649198], and give ABT -888 at the same dose. 
• For grade 3 or 4 nausea or vo miting, delay all subsequent protocol- directed therapy for 
a maximum of three  weeks until grade  ≤ 2, then decrease carboplatin  1 dose level, and 
give paclitaxel  and ABT -888 at the same dose.  
• If Induction (cycle 2) is delayed for more than three  weeks fo r mucositis, nausea, or 
vomiting , proceed to chemoradiotherapy. 
Alliance A091101  
 
Version Date: 08/11/2017  49 Update #07  6.1.6 Dose Modifications for Liver Function During Induction  
• For grade [ADDRESS_1277836], or alkaline phosphatase increase (CTCAE version 4.0, 
investigations section), delay all subsequent protocol -directed therapy for a maximum 
of three  weeks until  recovered until ALT, AST, and alkaline phosphatase improve to 
grade ≤ 2, then decrease paclitaxel  and carbolatin by [CONTACT_649198], 
and give the ABT- 888 at the same dose.  
• For grade > 1 blood bilirubin increase, delay all subsequent protocol -directed therapy 
for a maximum of three weeks until recovered until bilirubin level improved to grade ≤ 
1, then decrease paclitaxel and carboplatin 1 dose level and give ABT -888 at the 
previous dose.  
• If Induction (cycle 2) is delayed for more than three  weeks for abnormal liver function 
tests, proceed to chemoradiotherapy. 
6.1.7 Allergic Reactions  
• For grade 4 allergic reactions, or anaphylaxis, stop the infusion(s). Manage the reaction 
according to institutional procedure. Discontinue all protocol therapy. 
6.1.8 Other non -Hematologic Toxicity During Induction 
• For grade [ADDRESS_1277837] possibly related to 
treatment, delay all subsequent protocol -directed therapy for a maximum of three weeks 
until recovered to grade ≤ 1, then decrease the suspected drug(s) by [CONTACT_649198].  
• If Induction (cycle 2) is delayed for more than three  weeks, proceed to 
chemoradiotherapy. 
6.2 Dose Modi fications during Chemoradiotherapy, Option 1 (cisplatin) for phase I  
6.2.1 Hematologic Toxicity During Chemoradiotherapy 
• For grade 3 or 4 decrease in neutrophil count, delay cisplatin until ANC < grade 2, then give cisplatin at the planned dose (i.e., no dose reduction). If ANC does not improve to 
< grade 2 within 2 weeks, skip cisplatin. Continue radiotherapy. 
• For febrile neutropenia grade 3 or 4, wait for resolution before proceeding, and decrease cisplatin to 75mg/m
2 for the next dose. 
• For grade > 2 platelet count decrease; delay cisplatin until platelets improve to grade < 
1, then give cisplatin at the planned dose (i.e., no dose reduction). If thrombocytopenia 
does not improve to < grade 1 within 2 weeks, skip cisplatin.  Continue radiotherapy. 
• For any grade platelet count decrease associated with bleeding, decrease cisplatin to 75mg/m
2 for the next dose. 
6.2.2 GI Toxicity during Chemoradiotherapy 
• For grade 3 or 4 nausea or vomiting during cisplatin, hold next cycle until grade 2 or less, then give next cycle cisplatin 75mg/m
2 
• For grade 3 or 4 mucositis, continue cisplatin at same dose with no delays 
• For grade 3 or 4 dysphagia, continue cisplatin at same dose with no delays 
6.2.3 Skin Toxicity during C hemoradiotherapy 
For all grades radiation dermatitis, do not change dosing and do not delay cisplatin. 
Alliance A091101  
 
Version Date: 08/11/2017  50 Update #07  6.2.3 Neurotoxicity during Chemoradiotherapy 
• For grade 2 neurotoxicity decrease cisplatin to 75mg/m2.  Start/continue radiotherapy. 
• For grade [ADDRESS_1277838] atin. Continue radiotherapy. 
6.2.4 Ototoxicity  
• For grade 2 hearing impairment or grade 2 tinnitus, decrease cisplatin to 50mg/m2.  
• For grade 3 hearing impairment or grade 3 tinnitus, discontinue cisplatin.  
• For patients with hearing impairment, audiogram is encouraged.  
6.2.5 Nephrotoxicity  during Chemoradiotherapy  
• For CRCL 40 -50 mL/min, decrease cisplatin to 50 mg/m2 for that dose only.  
• For CRCL <40mL/min, discontinue cisplatin. Continue radiotherapy. 
6.3 Dose modifications during Chemoradiother apy, O ption 2 (hydroxyurea/5FU/paclitaxel) 
for phase I  
Dose levels for ch emotherapy during chemoradiotherapy  
 Hydroxyurea  5-FU Paclitaxel 
Dose Level     
0 500 mg every 12 hr. 
x 11 doses  600 mg/m2/day  100 mg/m2 
–1 500 mg every 24 hr. 
x 6 doses  500 mg/m2/day 75mg/ m2 
 
6.3.1 Hematologic toxicity  
• For grade 3 neutrophil count decreased on days of treatment in any cycle, decrease 
hydroxyurea by [CONTACT_490406]. Continue paclitaxel, 
5-FU and radiotherapy at the planned doses.  
• For grade 4 neutrophil count decrease on days of treatment in any cycle, skip 
hydroxyurea for this cycle, and decrease hydroxyurea by [CONTACT_742567]. Continue paclitaxel, 5 -FU, and radiotherapy at the planned doses. 
• For grade 2 platelet count decrease on days of treatment in any cycle, decrease 
hydroxyurea by [CONTACT_490406].  Continue paclitaxel, 5-FU and radiotherapy at the planned doses. 
• For grade 3 or 4 platelet count decrease on d ays of treatment in any cycle, skip 
hydroxyurea for this cycle and decrease paclitaxel and 5 -FU by [CONTACT_910224]. Decrease hydroxyurea by [CONTACT_137457]. Continue radiotherapy at the planned dose. 
• For > grade 2 neutrophil count decreased on any day of treatment with TFHX, 
administer filgrastim (or sargramostim per institutional procedures) SQ daily for [ADDRESS_1277839] 24 hours after the completion of 5- FU in this and all subsequent 
cycles.  
6.3.2  GI Toxicity During Chemoradiotherapy  
Alliance A091101  
 
Version Date: 08/11/2017  51 Update #07  • For grade 4 mucositis, oral, lasting > 7 days or present on day 1 of any cycle, decrease 
5-FU by [CONTACT_490406].  Continue hydroxyurea, 
paclitaxel, and radiotherapy at the planned doses.  
• For grade 4 diarrhea lasting > 7 days or present on day 1 of any cycle, decrease 5 -FU 
by [CONTACT_490406].  Continue hydroxyurea, paclitaxel, and radiotherapy at the planned doses. 
• For grade 4 dysphagia lasting > 7 days or present on day 1 of any cycle, decrease 5 -FU 
by [CONTACT_490406].  Continue hydroxyurea, paclitaxel, 
and radiotherapy at the planned doses. 
6.3.3 Skin Toxicity during Chemoradiotherapy  
For grade 4 radiation dermatitis (CTCAE Injury, poisoning, and procedural complications) lasting > 7 days or present on day 1 of any cycle, decrease 5-FU by [CONTACT_490407].  Continue hydroxyurea, paclitaxel , and radiother apy at the 
planned doses.  
6.3.4 Neuroto xicity during Chemoradiotherapy 
• For grade 2 peripheral neuropathy during chemoradiotherapy, decrease paclitaxel by 
[CONTACT_910225]. If neuropathy improves to grade 1 or less, 
can return to original dose level. Continue hydroxyurea and 5- FU at same dose.  
• For grade 3 or 4 peripheral neuropathy, discontinue paclitaxel. Continue hydroxyurea and 5FU at same dose.  
6.3.5 Nephrotoxicity During Chemoradiotherapy  
• For grade 2 nephrotoxicity, decrease hydroxyurea by [CONTACT_910226]. Do not change dose of paclitaxel or 5FU.  
• For grade [ADDRESS_1277840] or alkaline phosphatase increase (CTCAE version 4.0, Investigations section), skip hydroxyurea for this cycle only. 
6.3.[ADDRESS_1277841] possibly related to 
treatment, hold the suspected drug ONLY until toxicity improves to grade < 1, then add 
back and decrease the suspected drug(s) by [CONTACT_649198]. Do not make any changes in drugs that are not related to the toxicity, and do not delay any cycles due to 
toxicity.  
7.0 ADVERSE
 EVENTS:  LIST  AND  REPORTING  REQUIREMENTS  
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The following list of AEs ( Section 7.1 ) and the characteristics of an observed AE ( Section 7.2) will determine 
whether the event requires expedited reporting (via CTEP -AERS)  in addition to routine reporting.   
7.[ADDRESS_1277842] (CAEPR)  
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 
Alliance A091101  
 
Version Date: 08/11/2017  52 Update #[ADDRESS_1277843] (ASAEL), appears in a separate column and is identified with  bold 
and italicized  text. This subset  of AEs (ASAEL) contains events that are considered 'expected' 
for expedited reporting purposes only. Refer to the 'CTEP, NCI Guidelines: Adverse Event 
Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for 
further clarification. The CAEPR does not provide frequency data; refer to the Investigator's 
Brochure for this information. 
For protocols with CAEPRs not  including a “SPEER” category, protocol -specific exceptions to 
the CTEP -AERS  reporting table can be found in the CAEPR’s “ASAEL” category instead.   This 
protocol- specific exception is limited to Grade [ADDRESS_1277844] (CAEPR)  For ABT -888 
(Veliparib, NSC 737664) 
 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by [CONTACT_6764]. In addition to the comprehensive list,  a subset, the Specific Protocol 
Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are protocol specific 
exceptions to expedited reporting to NCI (except as noted below).  Refer to the 'CTEP, NCI 
Guidelines: Adverse Event Reporting Requirements' http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  for 
further clarification. Frequency is provided based on 2310 patients. Below is the CAEPR for ABT -
888 (Veliparib).  
 
NOTE: Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next to 
the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational agents and has an AE listed on different SPEERs, use the lower of the grades to 
determine if expedited reporting is required . 
Version 2.3, March 4, 201 61 
 
 
  
    
  
 
 
     
   
    
     
  
     
     
     
    
     
  
    
   

Alliance A091101  
 
Version Date: 08/11/2017  53 Update #07   
   
  
  
   
  
 
 
 
     
      
 
     
     
     
     
   
     
     
     
   
     
     
     
     
   
    
   
     
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412].   Your name, the name [CONTACT_6823], the protocol and the agent should 
be included in the e- mail.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A091101  
 
Version Date: 08/11/2017  54 Update #07   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
7.1.2 Radiation 
Radiation to the head and neck will cause skin irritation, dry mucous membranes due to 
salivary gland dysfunction, mucositis and stomatitis.  The concomitant administration of 
chemotherapy will aggravate these side effects.  Long -term side effects include myelitis, 
osteoradionecrosis, hoarseness, hypothyroidism, trismus, swallowing dysfunction, and fibrosis of soft tissues.  
7.1.3 Radiation Adverse Events  
Grade  3-4 therapy-induced mucositis  and/or dysphagia, which are enhanced by [CONTACT_181615], 
are expected  to develop in about two thirds of patients.  Nutritional evaluation  prior to the 
initiati on of therapy  for a prophylactic gastrostomy  (PEG) tube  placement  is highly 
recommended. Placement of a feeding  tube should be recorded,  as should use of a feeding 
tube during and after treatment (e.g., greater than or less than 50% of nutrition by  [CONTACT_181616]). 
Other common radiation adverse events  include: fatigue,  weight  loss, regional alopecia,  
xerostomia, hoarseness,  transient  ear discomfort, dysgeusia, and skin erythema and 
desquamation within  the treatment fields  

Alliance A091101  
 
Version Date: 08/11/2017  55 Update #07  Less common long- term treatment adverse even ts include: hypothyroidism, loss of hearing, 
chronic swallowing  dysfunction requiring permanent  feeding tube, and cervical fibrosis. 
Much less common  radiation  adverse events include: mandibular osteoradione crosis (< 5% 
incidence with attention to the dental recommendations provided  in Appendix VI), and 
cervical  myelopathy (<1% with restriction of spi[INVESTIGATOR_181586]  ≤ 45 Gy). 
7.2 Adverse Event Characteristics  
CTCAE term (AE description) and grade:  The descriptions and grading scales found in the 
revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_1277845] access to a copy of the CTCAE version 4.0.  A copy of the CTCAE version 4.0 ca n be 
downloaded from the CTEP web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.  
For expedited reporting purposes only:  
AEs for the agent  that are bold and italicized in the CAEPR ( i.e., those listed in the SPEER 
column, Section 7.1.1 ) should be reported through CTEP -AERS  only if the grade is above the 
grade provided in the SPEER. 
Other AEs for the protocol  that do not require expedited reporting are outlined in Sectio n 7.3.3. 
7.[ADDRESS_1277846] if a patient has an adverse event requiring expedited reporting. The descriptions and 
severity grading scales found in the NCI Common Terminology Criteria for Adverse Events 
(CTCAE)  version 4.[ADDRESS_1277847] access to a 
copy of the CTCAE version 4.0. It can be downloaded from the CTEP website  (http://ctep.cancer.gov). Be sure to read this entire protocol section, as requirements are  
described in both the table and bullet points following the table.  Note that the additiona l 
instru ctions or exclusions are protocol specific, and in the case of a conflict, the additional 
instructions or exclusions supercede the table.  
7.3.[ADDRESS_1277848] use CTEP -AERS  ( CTEP Adverse Event 
Reporting System),  accessed via the CTEP Web site (http://ctep.cancer.gov). The reporting 
procedures to be followed are presented in the “NCI Guidelines for Investigators:  Adverse 
Event Reporting Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs” which 
can be downloaded from the CTEP Web site (http://ctep.cancer.gov). These requirements 
are briefly outlined in the tables below ( Section 7.3.3).  In the r are occurrence when Internet 
connectivity is lost, a 24- hour notification is to be made to CTEP by [CONTACT_1381] 301-897-
7497. Once Internet connectivity is restored, the 24- hour notification phoned in must be 
entered electronically into CTEP- AERS  by [CONTACT_386231].  
7.3.2 CTEP -AERS  is programmed for automatic electronic distribution of reports to the following 
individuals: Protocol Coordinator, Study Chair, and the local treating physician. CTEP -
AERS  provides a copy feature for other e- mail recipi[INVESTIGATOR_840].  
7.3.3 Expedited Reporting Guidelines 
Note: A death on study requires both routine and expedited reporting regardless of causality, unless as noted below. Attribution to treatment or other cause must be provided. Use the 
Alliance A091101  
 
Version Date: 08/11/2017  56 Update #07  NCI protocol number and the protocol -specific patient ID assigned during trial registration 
on all reports.  
A091101: Expedited Reporting Requirements for Adverse Events that occur on studies u nder 
and IND within [ADDRESS_1277849] administration of the Investigational Agent/ Intervention1 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:   Investigators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 
312.64) 
An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death  
2) A life -threatening adverse event  
3) An adverse event that results in inpatient hospi[INVESTIGATOR_1328] ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_708], based upon medical judgment, they may 
jeopardize the patient or subject and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. (FDA,  21 CFR 312.32; ICH E2A and ICH E6).  
ALL  SERIOUS  adverse events that meet the above criteria MUST be immediately reported to the NCI 
via CTEP -AERS  within the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_317] 1 and Grade 2 Timeframes Grade 3 -5 
Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059] ≥ 24 hrs 10 Calendar Days 
24-Hour 5 Calendar Days 
Not res ulting in 
Hospi[INVESTIGATOR_059] ≥ 24 hrs Not required 
Expedited AE reporting timelines are defined as:  
• “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP -AERS  within 24 hours 
of learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 
24-hour report. 
• “10 Calendar Days” - A complete expedited report on the AE must be submitted within [ADDRESS_1277850] administration of treatment require 
reporting as follows:  
Expedited 24 -hour notification followed by [CONTACT_432] 5 calendar days for:  
• All Grade 3, 4, and Grade [ADDRESS_1277851] possibly related to treatment  
Expedited 10 calendar day reports for:  
• Grade [ADDRESS_1277852] 
possibly related to treatment 
Effective Date:  May 5, 2011  
Alliance A091101  
 
Version Date: 08/11/2017  57 Update #07  Additional instructions or exclusions to CTEP- AERS  expedited reporting requirements 
for Alliance A091101: 
Treatment expected adverse events include those listed in Section 8.0 and in the package inserts 
for carboplatin , cisplatin, 5- FU, hydroxyurea, paclitaxel, and in the CAEPR for ABT -888.  Note 
that in the CAEPR, the ASAEL has been replaced by [CONTACT_910227] (SPEER) list. The SPEER includes “expected” severity grades in addition 
to event terms. All of these expected adverse events do not require CTEP -AERS  reporting 
• Grade 3/4 hemat osuppression and hospi[INVESTIGATOR_910193] -AERS , but 
should be reported via routine data submission. 
• Grade 3/4 nausea or vomiting from cisplatin  or carboplatin , and hospi[INVESTIGATOR_910194] -AERS , but should be reported via routine data submission. 
•  Grade 3/4 dysphagia during chemoradiotherapy, and hospi[INVESTIGATOR_910195], do not 
require CTEP -AERS , but should be reported via routine data submission. 
• Grade 3/4 dehydration or increased creatinine from cisplatin, and hospi[INVESTIGATOR_910195], 
do not require CTEP -AERS , but should be reported via routine data submission. 
• Grad e 3/4 hypersensitivity reactions to carboplatin, cisplatin, or paclitaxel do not require 
CTEP -AERS, but should be reported via routine data reporting. 
• Deaths due to progressive disease do not require CTEP -AERS , but should be reported via 
routine data submission.  
• The reporting of adverse events via CTEP -AERS  is in addition to routine data submission, 
for those events requiring expedited reporting. 
• All new malignancies should be report ed through CTEP -AERS  independent of attribution to 
treatment.  This includes solid tumors (including non- melanoma skin cancers), hematologic 
malignancies, MOS, AML, and in -situ tumors. In CTCAE, new malignancies (second and 
secondary) may be reported as on e of the following: leukemia secondary to oncology 
chemotherapy, myelodysplastic syndrome, treatment -related secondary malignancy, or 
neoplasm other, malignant (grade 3 or 4). Whenever possible, CTEP -AERS  reports for new 
malignancies should include tumor pathology, history of prior tumors, prior treatment/ current treatment including duration, any associated risk factors or evidence regarding how long the new malignancy may have been present, when and how it was detected , molecular 
characterization or cytogenetics of the original and new malignancy (if available), and treatment and outcome of the new malignancy, if available.  
• All pregnancies and suspected pregnancies occurring in female patients during therapy or within 28 days after completion of therapy should be reported via CTEP -AERS . In CTCAE, 
pregnancy or suspected pregnancy should be reported as pregnancy, puerperium and perinatal conditions -other: fetal exposure (grade 4).  
7.[ADDRESS_1277853] also be reported in routine study data submissions. 
Alliance A091101  
 
Version Date: 08/11/2017  58 Update #07  8.0 PHARMACEUTICAL  INFORMATION 
8.1 CTEP IND Agent ABT -888 (NSC 737664; IND #[ZIP_CODE]; veliparib) 
Availability  
 
Clinical Supplies:   ABT -888 (veliparib, NSC 737664/ IND [ZIP_CODE]) and matching Placebo will 
be provided free of charge by [CONTACT_910228] (PMB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and 
Diagnosis (DCTD), National Cancer Institute (NCI).  
 
 
 
 
 
 
 
 Phase I Open -label drug orders: No open- label starter supplies will be available for this study.  
Patient -specifi c supplies will be sent to the registering investigator at the time of registration 
and should arrive within 7 to 10 days. Once a patient has been registered, the Alliance 
Registration/Randomization Office will electronically transmit a clinical drug reque st for that 
patient to the PMB. This request will be entered and transmitted by [CONTACT_910229]/Randomization Office the day the patient is registered and will be processed by 
[CONTACT_910230].  Shipments within the 
[LOCATION_002] will be sent by [CONTACT_910231] (up to 5 business days).  Shipments to [LOCATION_002] 
sites can be expedited by [CONTACT_910232]/Randomization Office at the  time the patient is registered/randomized.  
 
Initial supplies for patients registered to All Dose Levels  
The request will be for 64 capsule bottles of 50 mg ABT -888, a 2- cycle / 6 -week supply at the 
prescribed dose level given orally BID on days 1 through 7 of each cycle.  This supply will be 
sufficient for the patient to complete the prescribed maximum of two cycles of induction with ABT -888. 
 
Dose 
Cohort  ABT -888 (veliparib) Dose Supplies provided  
(50 mg capsules x 64 capsules/bottles)  
-3 50 mg BID x 7 days  1 bottle  
-2 100 mg BID x 7 days  2 bottles  
-1 150 mg BID x 7 days  2 bottles  
*0B 200 mg BID x 7 days  3 bottles  
1 250 mg BID x 7 days  3 bottles  
2 300 mg BID x 7 days  4 bottles  
3 350 mg BID x 7 days  4 bottles  
*starting dose level  
 
Note:  In order to dispense a single cycle at a time, ABT -888/placebo capsules may be 
repackaged from the supplied HDPE bottles into amber (or other low -actinic) child resistant 
pharmacy dispensing bottles. The bottles should be labeled according to State regulations and also include the information from the original patient specific bottle sent from the PMB.  

Alliance A091101  
 
Version Date: 08/11/2017  59 Update #07  Expi[INVESTIGATOR_372286] 30 days from the repackaging date (or the original retest date, whichever is 
earlier) when stored at 15°C to 25°C (59°F to 77°F). 
 
Note: Partial bottles of patient specific supplies remaining after completion of treatment should 
be destroyed on- site per institutional policy and be recorded on the patient specific 
accountability log.  
Phase II Blinded drug orders: Once the Phase II dose has been determined, a protocol 
amendment will be completed to incorporate appropriate ordering instructions. 
 
ABT -888 (veliparib) and matching Placebo will be supplied in bottles containing either 64 – 50 
mg capsules ABT -888 (veliparib) or 64 – 0 mg capsules [Placebo for 50 mg ABT -888 (veliparib)]  
with a child -resistant cap and a tamper- evident seal.   Each blinded, patient -specific bottle will 
be labeled with … 
 
• the protocol number (i.e., “A091101”) 
• the bottle number (i.e., “Bottle 1 of 2” and “Bottle 2 of 2”) 
• the number of capsules (i.e., “64  capsules”)  
• the patient ID number (e.g.,"9999999", where “9999999” represents the unique patient 
identifier assigned at registration)  
• the patient initials (i.e., first initial, last initial [e.g., "F ML"])  
• the agent identification [i.e., “ ABT -888 (veliparib) 50 mg or Placebo ”] 
• a blank line for the pharmacist to enter the patient’s name  
• administration instructions (i.e., “Take __ capsules twice daily.”)  
• storage instructions (i.e., “Store at room temperature ( 15ºC to 25ºC; 59ºF to 77ºF ).” 
• emergency contact [CONTACT_73875]  
• a Julian date  
 
The Julian date indicates the day the bottle was labeled and shipped and is composed of the last 
two digits of the calendar year (e.g., 2009 = 09, 2010 = 10) and a day  count (e.g., January  1 = 
001, December 31 = 365). For example, a bottle labeled and shipped on January 1, [ADDRESS_1277854] a Julian date of ‘[ZIP_CODE]’ and a bottle labeled and shipped on December 31, [ADDRESS_1277855] a Julian date of ‘[ZIP_CODE]’. The Julian date will be used by [CONTACT_675292]. The Julian date 
should be recorded in the Lot No. field on the drug accountability record (DARF).  When a lot 
expi[INVESTIGATOR_6054], PMB will determine the last date the expi[INVESTIGATOR_311303] (i.e., both ABT- 888 and Placebo) shipped on or before that date thus eliminating any chance of 
breaking the blind.  
 
Questions about drug orders, transfers, returns, or accountability should be addressed to the PMB by [CONTACT_3379] (240) 276- 6575 Monday through Friday between 8:30am and 4:30pm Eastern 
Time. You may also contact [CONTACT_311377] e-mail at: [EMAIL_8889]. 
 
Agent Transfers: Bottles MAY NOT be transferred from one patient to another patient or from 
one protocol to another protocol. All other transfers (e.g., a patient moves from one 
participating clinical site to another participating clinical site, the principal investig[INVESTIGATOR_136]or [INVESTIGATOR_136] a given clinical site changes) must be approved in advance by [CONTACT_452287]. To obtain an approval 
for transfer, investigators should complete and submit to the PMB (fax number [PHONE_13108]) 
a Transfer Investigational Agent Form available on the CTEP home page (http://ctep.cancer.gov). The patient ID number (e.g., "9999999"') and the patient initials (e.g., 
Alliance A091101  
 
Version Date: 08/11/2017  60 Update #07  "FML”) should be entered in the "Received on NCI Protocol No." and the "Transferred to NCI 
Protocol No." fields in addition to the protocol number (i.e., "A091101"). 
 
Agent Returns : Only undispensed clinical supplies should be returned to the PMB.  
When it is necessary to return study drug (e.g., sealed bottles remaining when a patient 
permanently discontinues protocol treatment, expi[INVESTIGATOR_629479]), investigators should return the study drug to the PMB using the NCI Return Drug List available 
on the CTEP home page (http://ctep.cancer.gov) or by [CONTACT_1340] (240) 276 -6575. The 
patient ID number (e.g., "9999999") and the patient initials (e.g., "FML") should be entered in 
the "Lot Number" field.  Opened bottles with remaining capsules should be documented in the 
patient -specific NCI  ORAL Investigational Agent Accountability Record (i.e., logged in as 
“returned by [CONTACT_4676]” and logged out as “destroyed on site”) and destroyed on- site in 
accordance with institutional policy.  
 
Agent Accountability : The investigator, or a responsible party designated by [CONTACT_093], 
must maintain a careful record of the receipt, disposition, and return of all drugs received from the PMB using the ORAL NCI Investigational Agent Accountability Record available on the 
CTEP home page (http://ctep.cancer.gov) or by [CONTACT_1340] (240) 276- 6575.  A separate 
NCI ORAL Investigational Agent Accountability Record must be maintained for each patient ID number (e.g., "9999999”) on this protocol (Phase I and Phase II).  
 Emergency Unblinding Proce dures (Phase II only): Unblinding can be done only in cases 
of an emergency.  Follow the directions below to unblind patient treatment.  Please note that, if a treatment assignment is unblinded, the patient must discontinue protocol therapy. Examples 
of em ergencies include 1) a life- threatening unexpected adverse event that is at least possibly 
related to the investigational agent and for which unblinding would influence treatment 
decisions; or 2) medication error, such as accidental overdose.  Expected adv erse events are 
listed in the “Toxicities” section below.  
 
Contact [CONTACT_910233] 773-702- 6800, pressing [ADDRESS_1277856] provide the following information to the Alliance Executive Officer:  
• Alliance study ID (i.e., “A091101”) • Alliance patient ID number (e.g., “9999999”) 
• Patient initials (e.g., “L,FM”)  
• Institution name 
• Name [CONTACT_669136] 
• Name [CONTACT_3669] [CONTACT_280082] 
• Name [CONTACT_3669] [CONTACT_280083] • Reason for emergency unblinding  
Please remember that emergency unblinding request may be authorized only by [CONTACT_910234], and emergency unblinding applies only if unblinding would influence management of the medical situation.  After the Executive Officer deems unblinding is 
warranted, the treatment assignment will be provided to the contact [CONTACT_280085].  
 
 
 
 
 

Alliance A091101  
 
Version Date: 08/11/2017  61 Update #07   
 
 
 
Administration: ABT -[ADDRESS_1277857] to meals.  
 
Potential Drug Interactions: Clinical studies evaluating the metabolism of ABT -[ADDRESS_1277858] not 
been conducted. However, results from the in vitro analysis reveal that this agent is metaboliz ed 
by [CONTACT_321876] – CYP1A1, 2D6, 2C19 and 3A4. ABT -[ADDRESS_1277859] parent drug along with metabolites suggesting 
that renal function plays an important role in the drug clearance and its metabolites.  
 
 
 
8.2 Commercial Agents  
8.2.1 Carboplatin  
Please refer to the package insert for full prescribing in formation. 
Availability : Carbopla tin is comm ercially available as a sterile lyophilized powder ava ilable 
in sin gle-dose vials containing 50  mg, 150 mg, or 450 mg of  carbopla tin.  Each vial contains 
equal par ts by [CONTACT_910235].  Comm ercial supplies of carbopla tin 
will be used for this study. C arboplatin is also ava ilable a s an aqueous solution in 50 mg/5 
mL, 150 mg /15 mL, 450 mg/45 m L and 600 mg /60 mL multid ose vials. 
Preparation: Reconstitute lyophil ized powder with St erile Water, 0.9% Sodium C hloride, or 
5% Dextrose Injection with volum es of diluents specified be low.  Th e reconstituted solution 
can be fur ther diluted to a c oncentration as low as 0.5 mg /mL with 0.9% Normal Sa line or 
5% Dextr ose Injection. 
Vial Strength  Diluent Volume  
50 mg   5 mL 
150 mg   15 mL 
450 mg   45 mL  
Storage  and Stability : When pre pared as di rected, the re sultant carbopla tin solutions,  when 
protected from light, are stable for 8 hours at r oom temperature. No antibacterial 
preserva tive is contained in the  formulation, a nd therefore, it is recommended that 
carbopla tin solutions be discarded 8 hour s after dilution.  
NOTE : Aluminum reacts with carbopla tin, causing prec ipi[INVESTIGATOR_492014]. Therefore, needles or intravenous sets c ontaining aluminum parts  that ma y 
come in contact [CONTACT_910236]. 
Unopened vials of carboplatin are stable for the li fe indi cated on the pac kage when stored 
at contr olled room te mperature (59 - 86°F) and pr otected from light. When p repared, 

Alliance A091101  
 
Version Date: 08/11/2017  62 Update #07  carbopla tin solutions are stable for 8 hours at r oom temperature. Carbopla tin aqueous 
solution  multidose vials maintain microbial, chemical, and phy sical stability for up to 14 
days a t 25º C  following multiple  needle entries. 
8.2.2 Cisplatin  
Formulation:  Cisplatin is a sterile aqueous solution, each mL containing 1 mg cisplatin and 
9 mg sodium chloride.  Cisplatin is supplied in multidose vials of 50 mg and 100 mg 
cisplatin.  
NOTE:  Aluminum reacts with cisplatin causing precipi[INVESTIGATOR_165987]; 
therefore, needles or intravenous sets containing aluminum parts that may come in contact 
[CONTACT_315643]. 
Storage and Stability: Storage Store intact vials at room temperature 15°C to 25°C (59°F to 
77°F) and protect from light. Do not refrigerate solution as a precipi[INVESTIGATOR_314963]. Further 
dilution stability is dependent on the chloride ion concentration and should be mixed in solutions of NS (at least 0.3% NaCl). After initial entry into the vial, solution is stable for 
[ADDRESS_1277860] 7 days under fluorescent room light at room 
temperature.  
Adverse effects : Leukopenia, thrombocytopenia, anemia, nausea, vomiting, nephrot oxicity, 
ototoxicity, peripheral neuropathy, electrolyte imbalance, hypocalcemia, hypomagnesemia, 
ocular toxicity, and allergic reactions.  Infrequent:  cardiac abnormalities, anorexia, elevated 
SGOT, rash, alopecia, and acute myeloid leukemia.   
NOTE:  Am inoglycoside antibiotics given before, with, or after cisplatin may potentiate 
renal toxicity and should be avoided whenever possible.   
Severe renal toxicity can largely be avoided by [CONTACT_219689] a diuresis before, during and 
after treatment.  Mild renal  dysfunction is a common complication (10%) of chronic therapy 
and may require discontinuation of therapy according to protocol specifications. 
Refer to package insert for complete details.  
Availability : Cisplatin is commercially available from Bristol Lab oratories Oncology 
Products. 
8.2.3 Fluorouracil 
5-Fluorouracil (Adria, OH) : commercially available as 10 ml ampules containing 
500 mg/10 ml.  No dilution is necessary for administration, but it may be further diluted in 
D5W or normal saline.  It is stored at room temperature and is stable for 24  hours.  It will 
be administered by [CONTACT_374120].  Please refer to the package insert for 
full prescribing information. 
8.2.4 Paclitaxel 
Paclitaxel: Please refer to the package insert for informati on on preparation and for full 
prescribing information.  
Drug interactions: There is a potential for interaction with Ketoconazole, which might 
interfere with paclitaxel metabolism. Contraindications: Known hypersensitivity to either 
paclitaxel or Cremaphor EL.  
8.2.5 Hydroxyurea 
Hydroxyurea (Bristol -Myers Squibb, Princeton, NY):  commercially available as 500  mg 
capsules. It is stored at room temperature and will be administered orally.  Please refer to 
Alliance A091101  
 
Version Date: 08/11/2017  63 Update #[ADDRESS_1277861] often in patients with a history of, or currently 
receiving, interferon therapy. Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, h ydroxyurea should 
be discontinued if cutaneous vasculitic ulcerations develop and alternative cytoreductive 
agents should be initiated as indicated. 
Geriatric Use :  Elderly patients may be more sensitive to the effects of hydroxyurea, and 
may require a lower dose regimen.   
This drug is known to be excreted by [CONTACT_10521], and the risk of toxic reactions to this drug 
may be greater in patients with impaired renal function. Because elderly patients are more 
likely to have decreased renal function, care should  be taken in dose selection, and it may 
be useful to monitor renal function. 
 
9.0 CORRELATIVE SCIENCE COMPANION STUDY 
Description of correlative science sample collection, analysis, and statistical consideration to be added after the completion of the Phase I portion of the study. 
Alliance A091101  
 
Version Date: 08/11/2017  64 Update #07  10.0 STUDY  CALENDAR   
Baseline evaluations are to be conducted <[ADDRESS_1277862] be done <4 weeks prior to the start of therapy.  In the event that the patient’s condition is 
deteriorating, laboratory evaluations should be repeated within 48 hours prior to initiation of the next 
cycle of therapy.   
 Pre-
Treatment  Treatment  Clinical Follow -Up 
Item  Pre-
therapy  Induction 
chemo - 
therapy 
(Wks 1 -6)* CRT**  2 wks 
after 
CRT  1 month 
after  
CRT  3 mos 
after 
CRT  Clinical 
Follow -
up*** 
History and physical  X X X  X X X X 
ENT/Surgeon’s 
evaluation1 X    X X X 
Tumor map  X       
Dental assessment  X   X X   
Barium s wallowing 
assessment2 X     X X 
Patient Medication 
Calendar `  X      
Performance status  X X X X X X X 
Concomitant meds 
assessment3  X X X  X X X  
Adverse events   X X  X X X X 
Imaging4 A B    X X 
CBC, diff, platelets  X weekly  X X X X X 
Electrolytes (Na, K, Cl, 
bicarb)  X weekly  X X X X X 
Mg, Ca, Phosphorous  X weekly  X X X X C 
AST, ALT, Alk. Phos. 
bili X weekly  X X X X X 
Albumin, total protein  X weekly  X X X X X 
Serum Creatinine  X w eekly  X X X X X 
Creatinine Clearance5 X X      
BUN  X weekly  X X X X X 
Glucose  X weekly  X X X X  
TSH, uric acid, PT/INR  As clinically indicated  
mvHPV status in 
Oropharyngeal tumors  X       
ECG  X       
Pregnancy test  X       
Biopsy  X As clinically indicated  
 
Alliance A091101  
 
Version Date: 08/11/2017  65 Update #07  * At the beginning of each c ycle, unless otherwise noted  
** Concurrent CRT therapy is to begin within 10 days  following the end of induction therapy. Tests and evaluations are to 
be done prior to beginning CRT, then weekly.  
*** 6, 12, 18, 24, 30, 36, 48, and 60 months following the end of CRT . Patients who progress will move to the Survival 
Only Follow -up Phase and be followed every 6 months through year 5. 
1. An examination  by [CONTACT_910237] & Ne ck Surgeon, includi ng laryng opharyn goscopy (mirr or and/or  fiberoptic 
and/or direct proce dure) . 
2. Barium s wallowing assessments should be performed pre-treatment and  in Months 10, 16, and 25 from the completion 
of chemoradiotherapy and as otherwise indicated.  
3. Document use of concomitant medications in physician or nursing note.  
4. The same imaging method should be used throughout the study.  
5. Can be calculated using C ockcroft -Gault formula. Recalculate if creatinine or weight change > 30%. In cases of low 
Creatinine Clearance or clinic disparities obtain 24 -hour urine for CrCl calculation.  
6. PT (INR) evaluation will be included at pre -therapy only unless otherwise indicated.  
A Pre-therapy imaging  options per physician preference:  a) CT scan of the neck (with contrast) and a chest CT scan 
(with or without contrast); b) or an MRI of the neck and a chest CT scan (with or without contrast); c) or a CT scan of 
neck (with c ontrast) and a PET/CT of neck and chest (with or without contrast) withi n [ADDRESS_1277863] week of induction chemotherapy (week 6), patients will undergo  primary endpoint image 
assessment. T he same evaluation method as pre -treatment imaging must be used.   
C Only calcium and not magnesium and phosphorous need be measured during clinical follow -up. 
11.[ADDRESS_1277864]  GUIDELINE  
NOTE:  This study uses protocol RECIST v1.1 template dated 2/16/2011.  See the footnote for the 
table regarding measureable disease in Section 11.4.4 , as it pertains to data collection and analysis.  
Response and progression will be evaluated in this study using the new inter national criteria proposed 
by [CONTACT_459] (RECIST) guidelines (version 1.1)52. 
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the short axis measurements in the case of lym ph nodes are used in the RECIST guideline . 
11.1 Schedule of Evaluations   
In order not to delay the start of concurrent CRT , patients should be reevaluated prior to 
concomitant CRT (during the last week  of induction chemotherapy ), where the response to 
induction c hemotherapy will be assessed and  measured (primary endpoint ). The same imaging 
evaluation method that was used pre-treatment should also be used for imaging during the last 
week of i nduction chemotherapy.  
11.2 Definitions of Measurable and Non- Measurable Disease 
11.2.1 Measurable Disease  
•  A non- nodal lesion is considered measurable if its longest diameter can be accurately 
measured as ≥2.[ADDRESS_1277865] x-ray, or as ≥1.[ADDRESS_1277866] component of a 
PET/CT, or MRI.  
•  A superficial non- nodal lesion is measurable if its longest diameter is ≥ 1.0 cm in diameter 
as assessed using calipers (e.g. skin nodules) or imaging.  In the case of skin lesions, 
documentation by [CONTACT_6775], including a ruler to estimate the size of the lesion, is  
recommended. • A malignant lymph node is considered measurable if its short axis is >1.[ADDRESS_1277867] scan (CT scan slice thickness recommended to be no greater than 5 mm).   
NOTE:  Tumor lesions in a previously irradiated area are not considered  measurable disease.   
Alliance A091101  
 
Version Date: 08/11/2017  66 Update #07  11.2.2 Non-Measurable Disease  
All other lesions (or sites of disease) are considered non -measurable disease, including 
pathological nodes (those with a short axis ≥1.0 to <1.5 cm).  Bone lesions, leptomeningeal 
disease, ascites, pleu ral/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory 
breast disease, and abdominal masses (not followed by [CONTACT_462]), are considered as non -
measurable as well.  
Note:  ‘Cystic lesions’ thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. However, if non- cystic lesions are present in the same patient, these are preferred for selection as target 
lesions.  In addition, lymph nodes that have a short  axis <1.0 cm are considered non-
pathological (i.e., normal) and should not be recorded or followed. 
11.3 Guidelines for Evaluation of Measurable Disease  
11.3.1 Measurement Methods:   
• All measurements should be recorded in metric notation (i.e., decimal fractions of 
centimeters) using a ruler or calipers.  
• The same method of assessment and the same technique must be used to characterize each 
identified and reported lesion at baseline and during follow -up. For patients having only 
lesions measuring at least [ADDRESS_1277868]- treatment tumor assessments.   
• Imaging -based evaluation is preferred to evaluation by [CONTACT_711105] a treatment.   
11.3.2 Acceptable Modaliti es for Measurable Disease:  
Conventional CT and MRI:  This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is [ADDRESS_1277869]:  If the site can document that the CT perf ormed as part of a PET -CT is of identical 
diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the 
PET-CT can be used for RECIST measurements and can be used interchangeably with 
conventional CT in accurately measuring cancer lesions over time.   
Chest X -ray:  Lesions on chest x -ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by [CONTACT_6776].  However, CT scans are preferable.  
Physical Examination:   For superficial non- nodal lesions, physical examination is 
acceptable, but imaging is preferable, if both can be done. In the case of skin lesions, documentation by [CONTACT_6775], including a ruler to estimate the size of the lesion, is 
recommended. 
FDG -PET:  FDG- PET scanning is allowed to complement CT scanning in assessment of 
progressive disease [PD] and particularly possible 'new' disease.  A ‘positive’ FDG -PET 
scanned lesion is defined as one which is FDG avid with an update greater than twice that 
of the surrounding tissue on the attenuation corrected image; otherwise, an FDG -PET 
Alliance A091101  
 
Version Date: 08/11/2017  67 Update #07  scanned lesion is considered ‘negative.’  New lesions on the basis of FDG -PET imaging can 
be identified according to the following algorithm: 
a. Negative FDG -PET at baseline with a positive FDG -PET at foll ow-up is a sign of PD 
based on a new lesion.  
b. No FDG -PET at baseline and a positive FDG -PET at follow -up:   
i. If the positive FDG -PET at follow -up corresponds to a new site of disease 
confirmed by [CONTACT_4654], this is PD.   ii. If the positive FDG- PET at follow -up is not confirmed as a new site of disease on 
CT at the same evaluation, additional follow -up CT scans (i.e., additional follow -up scans 
at least 4 weeks later) are needed to determine if there is truly progression occurring at 
that site. In this situation, the date of PD will be the date of the initial abnormal PDG -PET 
scan.   
iii If the positive FDG- PET at follow -up corresponds to a pre -existing site of disease 
on CT that is not progressing on the basis of the anatomic images, it is not classified as PD. 
c. After concurrent chemoradiotherapy, FDG -PET may be used to upgrade a response to a 
CR in a manner similar to a biopsy in cases where a residual radiographic abnormality is 
thought to represent fibrosis or scarring.  This post -treatment FDG -PET should be 
performed within 8- [ADDRESS_1277870] be acknowl edged 
that both approaches may lead to false positive CR due to limitations of FDG -PET and 
biopsy resolution/sensitivity. 
11.[ADDRESS_1277871]  
11.4.1 Target Lesions & Target Lymph Nodes 
• Measurable lesions (as defined in Section 11.2.1 ) up to a maximum of 5 lesions , 
representative of all involved organs, should be identified as “Target Lesions” and recorded 
and measured at baseline.  These lesions can be non- nodal or nodal (as defined in 11.2.1), 
where no more than 2 lesions are from the same organ and no more than 2 malignant nodal lesions are selected.  
Note:  If fewer than 5  target lesions and target lymph nodes are identified (as there often will 
be), there is no reason to perform additional  studies beyond those specified in the protocol 
to discover new lesions.   
• Target lesions and target lymph nodes should be selected on the basis of their size, be 
representative of all involved sites of disease, but in addition should be those that lend 
themselves to reproducible repeated measurements.  It may be the case that, on occasion, 
the largest lesion (or malignant lymph node) does not lend itself to reproducible 
measurements in which circumstance the next largest lesion (or malignant lymph node) 
which can be measured reproducibly should be selected.   
• Baseline Sum of Dimensions (BSD):  A sum of the longest diameter for all target lesions 
plus the sum of the short axis of all the target lymph nodes will be calculated and reported 
as the baseline sum of dimensions (BSD).  The BSD will be used as reference to further 
characterize any objective tumor response in the measurable dimension of the disease.   
• Post -Baseline Sum of the Dimensions (PBSD):  A sum of the longest diameter for all target 
lesions plus the sum of the short axis of all the target lymph nodes will be calculated and 
reported as the post -baseline sum of dimensions (PBSD).  If the radiologist is able to provide 
an actual measure for the target lesion (or target lymph node), that should be recorded, even 
Alliance A091101  
 
Version Date: 08/11/2017  68 Update #07  if it is below 0.5 cm.  If the target lesion (or target lymph node) is believed to be present and 
is faintly seen but too small to measure, a default value of 0.[ADDRESS_1277872] that the target lesion or target lymph node has likely 
disappeared, the measurement should be recorded as 0 cm.  
The minimum sum of the dimensions (MSD) is the minimum of the BSD and the PBSD. 
11.4.2 Non-Target Lesions & Non-Target Lymph Nodes 
Non-measurable sites of disease ( Section 11.2 .2) are  classified as non - target lesions or non-
target lymph nodes  and should also be recorded at  baseline.  These lesions and lymph nodes 
should be followed in accord with Section 11.4.3. 
11.4.[ADDRESS_1277873]/MRI/PET -CT/Chest X -
ray/physical examination must be measured on re- evaluation at evaluation times specified 
in Section 11.1.  Specifically, a change in objective status to either a PR or CR c annot be 
done without re- measuring target lesions and target lymph nodes.  
Note: Non-target lesions and non- target lymph nodes should be evaluated at each 
assessment, especially in the case of first response or confirmation of response.  In selected circum stances, certain non -target organs may be evaluated less frequently.  For example, 
bone scans may need to be repeated only when complete response is identified in target 
disease or when progression in bone is suspected. 
Evaluation of Target Lesions 
Complet e Response (CR):  All of the following must be true:  
a. Disappearance of all target lesions.  
b. Each target lymph node must have reduction in short axis to <1.0 cm. 
Partial Response (PR):  At least a 30% decrease in PBSD (sum of the longest diameter for 
all target lesions plus the sum of the short axis of all the target lymph nodes at current 
evaluation) taking as reference the BSD ( see Section 11.4.1).  
Progression (PD):  At least one of the following must be true: 
a. At least one new malignant lesion, which also includes any lymph node that was 
normal at baseline (< 1.0 cm short axis) and increased to ≥ 1.[ADDRESS_1277874] a 20% increase in PBSD (sum of the longest diameter for all target lesions 
plus t he sum of the short axis of all the target lymph nodes at current evaluation) taking as 
reference the MSD ( Section 11.4.1).  In addition, the PBSD must also demonstrate an 
absolute increase of at least 0.5 cm from the MSD.  
See Section 11.3.2  for details in regards to the requirements for PD via FDG -PET imaging.  
 Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR, nor sufficient 
increase to qualify for PD taking as reference the MSD.  
Evaluation of Non- Target Lesions & Non -target Lymph Nodes  
Complete Response (CR): All of the following must be true:  
a. Disappearance of all non -target lesions.  
b. Each non-target lymph node must have a reduction in short axis to <1.0 cm. 
Non-CR/Non -PD: Persistence of one or more non -target lesions or non -target lymph nodes.  
Progression (PD):  At least one of the following must be true: 
Alliance A091101  
 
Version Date: 08/11/2017  69 Update #[ADDRESS_1277875] one new malignant  lesion, which also includes any lymph node that 
was normal at baseline (< 1.0 cm short axis) and increased to ≥ 1.0 cm short axis during 
follow-up.   
b. Unequivocal progression of existing non- target lesions and non- target lymph 
nodes.  (NOTE:  Unequivocal progression should not normally trump target lesion and target 
lymph node status.  It must be representative of overall disease status change.)  
c. See Section 11.3.2 for details in regards to the requirements for PD via FDG -PET 
imaging.  
11.4.4 Overall Objective Status 
The overall objective status for an evaluation is determined by [CONTACT_300830]’s status on target lesions, target lymph nodes, non -target lesions, non- target lymph nodes, and new 
disease as defined in the following tables:  
For Patients with Measura ble Disease  
Target Lesions &  
Target Lymph Nodes  Non-Target Lesions &  
Non-Target Lymph 
Nodes  New  
Sites of Disease  Overall Objective 
Status  
CR CR No CR 
CR Non-CR/Non -PD No PR 
PR CR 
Non-CR/Non -PD No PR 
CR/PR  Not All Evaluated*  No PR**  
SD CR 
Non-CR/Non -PD 
Not All Evaluated*  No SD 
Not all Evaluated  CR 
Non-CR/Non -PD 
Not All Evaluated*  No Not Evaluated 
(NE)  
PD Unequivocal PD  
CR 
Non-CR/Non -PD 
Not All Evaluated*  Yes or No  PD 
CR/PR/SD/PD/Not all 
Evaluated  Unequivocal PD  Yes or No  PD 
CR/PR/SD/PD/Not all 
Evaluated  CR 
Non-CR/Non -PD 
Not All Evaluated*  Yes PD 
*See Section 11.4.3  
** NOTE:  This study uses the protocol RECIST v1.1 template dated 2/16/2011.  For data collection and analysis purposes the objective status changed from SD to PR in the NCCTG 
protocol RECIST v1.1 template as of 2/16/[ADDRESS_1277876] v1.1 requirements. 
11.4.5 Symptomatic Deterioration  
 Patients with global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time, and not either related to study 
treatment or other medical conditions, should be reported as PD due to “symptomatic 
deterioration.”  Every effort should be made to document the objective progress ion even 
after discontinuation of treatment due to symptomatic deterioration.  A patient is classified 
Alliance A091101  
 
Version Date: 08/11/2017  70 Update #07  as having PD due to “symptomatic deterioration” if any of the following occur that are not 
either related to study treatment or other medical conditions: 
Worsening of tumor- related symptoms.  
Decline in performance status of >1 level on ECOG scale.  
11.5 Formal statistical definitions  
Formal statistical definitions of analysis variables involving response and disease progression 
are contained in Section 13.0. 
12.0 DATA  REPORTING  / REGULATORY  REQUIREMENTS  
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0  
(Adverse Events: List and Reporting Requirements). 
12.1 Data Reporting 
12.1.1 Method  
This study will be monitored by [CONTACT_470] (CDUS) Version 3.0.  
Cumulative protocol - and patient -specific CDUS data will be submitted electronically to 
CTEP on a quarterly basis, either by [CONTACT_190791].  
Reports are due January 31, April 30, July 31, and October 31.  Instructions for submitting 
data using the CDUS can be found on the CTEP Web site 
(http://ctep.cancer.gov/reporting/cdus.html).    
Note :  If your study has been assigned to CDUS -Complete reporting, all adverse events 
(both routine and expedited) that have occurred on the study and meet the mandatory CDUS 
reporting guidelines must be reported via the monitoring method identified above.  If your 
study has been assigned to CDUS -Abbreviated reporting, no adverse event reporting 
(routine or expedited) is required to be reported via CDUS. 
12.1.[ADDRESS_1277877]® for remote data capture (RDC) of all study data. The Rave system can be accessed through the iMedidata portal at https://login.imedidata.com. 
For additional information regarding account setup or training, please visit the training section of the Alliance  website.  
Common Terminology Criteria for Adverse Events: This study will utilize the Common 
Terminolog y Criteria for Adverse Events (CTCAE) version 4.0 for toxicity and adverse 
event reporting. 
12.2 Collaborative Agreements Language 
The agent(s) supplied by [CONTACT_472], DCTD, NCI used in this protocol is/are provided to the NCI 
under a Collaborative Agreement (CR ADA, CTA, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the following obligations/guidelines, in addition to the 
provisions in the “Intellectu al Property Option to Collaborator” 
http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ) contained within the 
terms of award, apply to the use of the Agent(s) in this study: 
1.   Agent(s) may not be used for any purpose outside the scope of this protocol, nor can 
Agent(s) be transferred or licensed to any party not participating in the clinical study.  
Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and shall be 
maintained as such by [CONTACT_329236].  The protocol documents for studies utilizing Agents 
Alliance A091101  
 
Version Date: 08/11/2017  71 Update #07  contain confidential information and should not be shared or distributed without the permission 
of the NCI.  If a copy of this protocol is requested by a patient or patient’s family member 
participat ing on the study, the individual should sign a confidentiality agreement.  A suitable 
model agreement can be downloaded from: http://ctep.cancer.gov. 
2.   For a clinical protocol where there is an investigational Agent used in combination with 
(an)other Ag ent(s), each the subject of different Collaborative Agreements, the access to and 
use of data by [CONTACT_474] (data pertaining to such combination use 
shall hereinafter be referred to as "Multi -Party Data”):  
a.  NCI will provide al l Collaborators with prior written notice regarding the existence and 
nature of any agreements governing their collaboration with NCI, the design of the proposed 
combination protocol, and the existence of any obligations that would tend to restrict NCI's 
participation in the proposed combination protocol. 
b.  Each Collaborator shall agree to permit use of the Multi -Party Data from the clinical trial 
by [CONTACT_25544], obtain regulatory approval or commercialize its own Agent.  
c.  Any Collaborator having the right to use the Multi- Party Data from these trials must agree 
in writing prior to the commencement of the trials that it will use the Multi -Party Data solely for 
development, regulatory approval, and commercialization of its own Agent. 
3.   Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement 
will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless 
additional disclosure is required by [CONTACT_34009] ( http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm).  
Additionally, all Clinical Data and Results and Raw Data will be collected, used and disclosed 
consistent with all applicable federal statutes and regulations for the protection of human subjects, including, if applicable, the Standards for Privacy of Individually Identifiable Health 
Information set forth in [ADDRESS_1277878] be sent to the 
NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or PI [INVESTIGATOR_349]) of Collaborator's wish to contact [CONTACT_476]. 
5.   Any data provided to Collaborator(s) for Phase [ADDRESS_1277879] be in accordance with the 
guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC 
for this clinical trial.  
6.   Any manuscripts reporting the results of this clinical trial must be provided to CTEP by 
[CONTACT_477] [INVESTIGATOR_350]-
Cooperative Group studies for immediate delivery to Collaborator(s) for advisory review and 
comment prior to submission for publication.  Collaborator(s) will have [ADDRESS_1277880] that publication be delayed for 
up to an additional 30 days in order to ensure that Collaborator’s confidential and propr ietary 
data, in addition to Collaborator(s)’s intellectual property rights, are protected.  Copi[INVESTIGATOR_867270](s) for courtesy review as 
soon as possible and preferably at least three (3) days prior to submission, but in any case, prior 
to presentation at the meeting or publication in the proceedings. Press releases and other media presentations must also be forwarded to CTEP prior to release.  Copi[INVESTIGATOR_352], 
abstract and/or press release/ media presentation should be sent to: 
Email: [EMAIL_001]  
Alliance A091101  
 
Version Date: 08/11/2017  72 Update #07  The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No publication, 
manuscript or other form of public disclosure shall contain any of Collaborator’s confidenti al/ 
proprietary information. 
13.0 STATISTICAL  CONSIDERATIONS  
13.1 Study Design/Endpoints  
13.1.1 Phase 1  
The maximum tolerated dose (MTD) will be determined in the Phase I portion of this trial. 
Patients will be placed in one of the dose cohorts of ABT-888 listed in Section 5.1.1, using 
a conventional 3+3 design. All patients will receive concomitant paclitaxel and carboplatin . 
The initial dose cohort is anticipated to be 30 mg BID (Abbott Personal Communication) and, together with doses for subsequent cohorts will be adjusted at the time of protocol 
initiation based on available data from other phase I studies in discussion with Abbott 
Pharmaceuticals and NCI.  The Alliance will notify CTEP when the Recommended Phase II 
Dose ( RP2D) is reached, and an amendment will be submitted to open the phase II portion 
of the study. 
13.1.2 Randomized Phase 2  
The primary endpoint will be the relative change in tumor size following 2 cycles of 
induction, rather than a dichotomous objective response rate.
50,51 This trial design is based 
on the ratio of tumor size measurements (post -treatment/baseline) which has been shown to 
follow the log -normal distribution; a two -sample t-test is then commonly used to compare 
the log -ratios between treatment arms. Tumor size will be measured using the RECIST 
criteria (i.e. the sum of the longest diameters of all target lesions will be used). The advantage of using continuous tumor size change is the reduction in sample size relative to 
a two -arm design with a d ichotomous endpoint, which can be 44% -64% under several 
scenarios considered by [CONTACT_288450]. Furthermore, a single- arm trial will not be appropriate due 
to the lack of reliable historical data.  
Formulated in terms of “good response” rate following induction chem otherapy (defined as 
> 50% reduction in the sum of target lesions), detecting a difference between 20% vs. 40% 
"good response" rates would be of interest. This difference in proportions corresponds to a difference in log -ratios of -1.091 versus -1.453. Based on the tumor size changes among 
patients enrolled on the carboplatin- paclitaxel  induction regimen in UC protocol 13362B [ A 
Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients with N2/N3 Locally Advanced Head and Neck Cancer ], the standard deviation (SD) of the log -
ratios of tumor size change was SD=0.616, and the log -normality assumption was satisfied. 
Because a CR rate of 5 -10% is expected based on prior trials with induction chemotherapy 
at the University of Chicago, the us e of a t-test would be problematic, given that the log-
ratio will be undefined for CR's. Instead, patients with CR will be assigned the lowest rank (lower rank corresponds to better outcome), and treatment arms will be compared using the 
nonparametric Wilcoxon rank- sum test. Similarly, patients who die during treatment will be 
assigned the highest rank (corresponding to the worst outcome).  
An interim analysis for futility will be performed when half of the patients have completed 
induction. The trial will be stopped early if the sum of ranks is lower than expected in the 
placebo arm and the Wilcoxon rank- sum test statistic is Z<0, i.e. when the interim analysis 
does not favor the treatment group. 
A simulation study was performed to determine the sample size. Data were generated from 
a mixture distribution where the outcome was CR with probability p
j, not evaluable (drop-
Alliance A091101  
 
Version Date: 08/11/2017  73 Update #07  out or death) with probability dj, and lognormally distributed with probability (1 - pj - dj);  
j=1,2 denotes placebo and ABT -888 arms, respectively. An early stoppi[INVESTIGATOR_910196]. The following scenario was considered: CR rates p1=0.05 and p 2=0.10; drop-
our rates d1=0.10 and d2=0.07 (assuming fewer deaths in the ABT -888 arm); tumor size log -
ratios distributed with μ 1 = -1.091, μ 2=-1.091 and σ 1 = σ2 = 0.616 (as described above). Based 
on R=10,000 simulations, the sample size of 46 patients/arm (92 total) will have 81% power 
with one -sided α=0.05. Note that the sample size is almost 45% less than 64 patients/arm 
that would be required for a randomized two- arm trial comparing response rates.  
13.2 Sample Size/Accrual Rate  
We plan to enroll 18 patients in the Phase 1 portion of the study at an accrual rate of 1 to 4 
patients per month. In the Phase 2 portion we plan to enroll  92 patient s, at an accrual rate of 5 
to 10 pa tients per month. Study accrual will be monitored and an accrual plan will be instituted 
if deemed necessary.  
 
TARGETED/PLANNED ENROLLMENT - NUMBER OF SUBJECTS  
 
 
 
 Hispanic or Latino Category  
  Phase I/II Trial – total anticipated sample 
size is up to 110 subjects (up to 18 subjects to be enrolled in the Phase I portion and 46 patients per 
induction chemotherapy treatment arm).  
Sex 
Female  Male  Total  
Hispanic or Latino  3 7 10 
Not Hispanic or Latino  20 80 100 
Ethnic Category: Total of All Subjects  23 87 110 
Racial Categories     
Others and Mixed  1 2 3 
Asian  2 3 5 
Black or AA  8 22 30 
White or Caucasian  12 60 72 
Ethnic Categories: Total of All Subjects  23 87 110 
 
13.3 Stratification Factors  
13.3.1 Phase II:  
In the Phase II part of this trial, patients will be randomized in a double -blinded fashion t o 
induction therapy with carboplatin and paclitaxel  plus ABT -888 or placebo ; and the patient's 
subsequent therapy will be determined by [CONTACT_910238]. Randomization will be stratified by [CONTACT_20150]/nodal 
status (T1 -3 and N0-N2a versus T4 and/or N2b- N3 respectively ), oropharyngeal 
disease/HPV status  (non-oropharyngeal disease versus  oropharyngeal disease with HPV 
positive status versus  oropharyngeal disease with HPV negative status) and institution  
(implicitly stratifies by [CONTACT_910214], as it is planned that concomitant CRT will be an institution level choice)  and permuted blocks will be used to balance patient allocation. 
13.4 Analysis of Secondary Endpoints  
Secondary endpoints include evaluation and comparison of toxicity rates during induction and overall; time -to-event endpoints [progression- free survival (PFS), disease- free survival (DFS), 
Alliance A091101  
 
Version Date: 08/11/2017  74 Update #07  time to local or distant progression, disease -specific survival (DS S), and overall survival (OS)]. 
Toxicity rates will be summarized by [CONTACT_19313], and compared between groups using the chi -
squared or Fisher's exact test. Time -to-event endpoints (PFS, DFS and OS) will be summarized 
using the method of Kaplan- Meier, and compare d between groups using the log- rank test. 
Multivariate Cox proportional hazards regression models will be used to further explore group 
differences adjusting for other prognostic factors, as well as to estimate hazard ratios. Cause-
specific survival will b e summarized using cumulative incidence, and will be compared between 
groups using Gray's test. Other methods appropriate for the analysis of competing risks data (e.g. Fine- Gray regression models) may also be used . 
13.[ADDRESS_1277881] be assessed for response to treatment, even if there 
are major prot ocol treatment deviations or if they are ineligible.  Each patient will be 
assigned one of the following categories:  1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early deat h from 
toxicity, 7) early death because of other cause, or 9) unknown (not assessable, insufficient data).  [Note:  By [CONTACT_480], category 9 usually designates the “unknown” status 
of any type of data in a clinical database.]  
All of the patients  who met the eligibility criteria (with the possible exception of those who 
received no study medication) should be included in the main analysis of the response rate.  The 95% confidence interval will also be provided. Patients in response categories [ADDRESS_1277882] a treatment failure (disease progression).  Thus, an incorrect treatment schedule or drug administration does not result in exclusion from the analysis of 
the response rate.  Precise definitions for categories [ADDRESS_1277883] been identified (e.g., early death due to other reasons, early discontinuation of 
treatment, major protocol violations, etc.).  However, these subanalyses may not serve as 
the basis for drawing conclusions concerning treatment efficacy, and the reasons for excluding patients from the analysis should be clearly reported  
  
Alliance A091101  
 
Version Date: 08/11/2017  75 Update #07  14.0 REFERENCES  
1. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous 
cell carcinoma of the head and neck region. A meta -analysis of prospective and randomized trials. 
Journal of Clinical Oncology. March 1, 1996 1996;14(3):838-847. 
2. Pi[INVESTIGATOR_286978], Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for 
head and neck squamous -cell carcinoma: three meta- analyses of updated individual data. The Lancet. 
2000;355(9208):949-955. 
3. Pi[INVESTIGATOR_119603] J -P, le Maitre A, Bourhis J. Meta -Analyses of Chemotherapy in Head and Neck Cancer 
(MACH- NC): An Update. International Journal of Radiation Oncology*Biology*Physics. 
2007;69(2, Supplement 1):S112-S114. 
4. Pi[INVESTIGATOR_119603] J -P, Maître Al, Maillard E, Bourhis J . Meta -analysis of chemotherapy in head and neck 
cancer (MACH -NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and 
Oncology. 2009;92(1):4-14. 
5. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of conc urrent 
accelerated radiation plus cisplatin with or without cetuximab for stage III -IV head and neck 
squamous cell carcinomas (HNC). ASCO Meeting Abstracts. June 9, 2011 2011;29(15_suppl):5500. 
6. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of fa ilure, prognostic factors and survival 
in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-
year, 337- patient, multi- institutional experience. Annals of Oncology. August 1, 2004 
2004;15(8):1179-1186. 
7. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in 
unresectable head and neck cancer. N Engl J Med. Oct 25 2007;357(17):1695-1704. 
8. Hitt R, Grau JJ, Lopez -Pousa A, et al. Final results of a randomized phase III trial comparing 
induction chemotherapy with cisplatin/5- FU or docetaxel/cisplatin/5 -FU follow by 
[CONTACT_456374] (CRT) versus CRT alone as first -line treatment of unresectable locally advanced 
head and neck cancer (LAHNC). J Clin Oncol (Meeting Abstracts). May 20, 2009 
2009;27(15S):6009-. 
9. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by [CONTACT_374129]. Clin Cancer Res. 
Dec 1 2003;9(16 Pt 1):5936-5943. 
10. Salama JK , Stenson KM, Kistner EO, et al. Induction chemotherapy and concurrent 
chemoradiotherapy for locoregionally advanced head and neck cancer: a multi -institutional phase II 
trial investigating three radiotherapy dose levels. Annals of Oncology. October 1, 2008 
2008;19(10):1787-1794. 11. León X, Quer M, Orús C, del Prado Venegas M, López M. Distant metastases in head and 
neck cancer patients who achieved loco -regional control. Head & Neck. 2000;22(7):680-686. 
12. Ang KK, Harris J, Wheeler R, et al. Human papi[INVESTIGATOR_910197]. N Engl J Med. Jul 1 2010;363(1):24-35. 
13. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. Aug 
2004;26(8):882-893. 
14. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S , Taniguchi T. Enhanced 
expression of poly(ADP -ribose) synthetase gene in malignant lymphoma. Am J Hematol. Aug 
1991;37(4):223-227. 
Alliance A091101  
 
Version Date: 08/11/2017  76 Update #07  15. Shiobara M, Miyazaki M, Ito H, et al. Enhanced polyadenosine diphosphate -ribosylation 
in cirrhotic liver and carcinoma t issues in patients with hepatocellular carcinoma. J Gastroenterol 
Hepatol. Mar 2001;16(3):338-344. 
16. Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP -ribose) synthesis in human cervical 
cancer cell -diagnostic cytological usefulness. Cancer Lett. Dec 1981;14(3):227-236. 
17. Alderson T. New targets for cancer chemotherapy --poly(ADP- ribosylation) processing and 
polyisoprene metabolism. Biol Rev Camb Philos Soc. Nov 1990;65(4):623-641. 
18. Wielckens K, Garbrecht M, Kittler M, Hilz H. ADP -ribosylation of n uclear proteins in 
normal lymphocytes and in low -grade malignant non-Hodgkin lymphoma cells. Eur J Biochem. Feb 
1980;104(1):279-287. 
19. Berger NA, Adams JW, Sikorski GW, Petzold SJ, Shearer WT. Synthesis of DNA and 
poly(adenosine diphosphate ribose) in no rmal and chronic lymphocytic leukemia lymphocytes. J Clin 
Invest. Jul 1978;62(1):111-118. 
20. Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate -ribose) 
metabolism in human colon adenomatous polyps and cancers. Cancer Res. Jul 1983;43(7) :3441-
3446. 
21. Fernet M, Ponette V, Deniaud- Alexandre E, et al. Poly(ADP -ribose) polymerase, a major 
determinant of early cell response to ionizing radiation. Int J Radiat Biol. Dec 2000;76(12):1621-
1629. 
22. Shall S, de Murcia G. Poly(ADP -ribose) polymer ase-1: what have we learned from the 
deficient mouse model? Mutat Res. Jun 30 2000;460(1):1-15. 
23. Masutani M, Nozaki T, Nakamoto K, et al. The response of Parp knockout mice against 
DNA damaging agents. Mutat Res. Apr 2000;462(2-3):159-166. 24. Ame JC, R olli V, Schreiber V, et al. PARP -2, A novel mammalian DNA damage -
dependent poly(ADP -ribose) polymerase. J Biol Chem. Jun 18 1999;274(25):[ZIP_CODE]-[ZIP_CODE]. 
25. Menissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP -1 
and PARP -2 in chromosome stability and embryonic development in mouse. Embo J. May 1 
2003;22(9):2255-2263. 26. Schreiber V, Ame JC, Dolle P, et al. Poly(ADP -ribose) polymerase- 2 (PARP -2) is required 
for efficient base excision DNA repair in association with PARP -1 and XRCC1. J Biol Chem. Jun 21 
2002;277(25):[ZIP_CODE]-[ZIP_CODE]. 
27. Johansson M. A human poly(ADP -ribose) polymerase gene family (ADPRTL): cDNA 
cloning of two novel poly(ADP -ribose) polymerase homologues. Genomics. May 1 1999;57(3):442-
445. 
28. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP -ribose) polymerase -1-
dependent cell death by [CONTACT_20983]-inducing factor. Science. Jul 12 2002;297(5579):259-263. 
29. D'Am ours D, Sallmann FR, Dixit VM, Poirier GG. Gain-of- function of poly(ADP -ribose) 
polymerase- 1 upon cleavage by [CONTACT_372373]: implications for apoptosis. J Cell Sci. Oct 
2001;114(Pt 20):3771-3778. 30. Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res. Jun 30 
2000;451(1-2):39-51. 31. Ruscetti T, Lehnert BE, Halbrook J, et al. Stimulation of the DNA -dependent protein 
kinase by [CONTACT_52362](ADP-ribose) polymerase. J Biol Chem. Jun 5 1998;273(23):[ZIP_CODE]-[ZIP_CODE]. 
Alliance A091101  
 
Version Date: 08/11/2017  77 Update #07  32. Galande S, Kohwi -Shigemat su T. Poly(ADP -ribose) polymerase and Ku autoantigen form 
a complex and synergistically bind to matrix attachment sequences. J Biol Chem. Jul 16 
1999;274(29):[ZIP_CODE]-[ZIP_CODE]. 
33. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP -ribose) 
polymerase and DNA -dependent protein kinase on cellular responses to DNA damage. 
Carcinogenesis. Feb 1999;20(2):199-203. 
34. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of 
base excision repair sensitizes mismatch repair -deficient and -proficient colon cancer cells to 
methylating agents. Clin Cancer Res. Oct 1999;5(10):2908-2917. 
35. Jagtap P, Szabo C. Poly(ADP -ribose) polymerase and the therapeutic effects of its 
inhibitors. Nat Rev Drug Discov. May 2005;4(5):421-440. 
36. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2- deficient tumours 
with inhibitors of poly(ADP -ribose) polymerase. Nature. Apr 14 2005;434(7035):913-917. 
37. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA  mutant 
cells as a therapeutic strategy. Nature. Apr 14 2005;434(7035):917-921. 
38. Masutani M, Suzuki H, Kamada N, et al. Poly(ADP -ribose) polymerase gene disruption 
conferred mice resistant to streptozotocin -induced diabetes. Proc Natl Acad Sci U S A. Mar 2 
1999;96(5):2301-2304. 
39. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP -ribose) 
polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A. Jul 8 
1997;94(14):7303-7307. 
40. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and 
DNA repair inhibition by [CONTACT_372374] -dependent protein kinase and 
poly(ADP -ribose) polymerase-1. Cancer Res. Sep 15 2003;63(18):6008-6015. 
41. Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA. Radiosensitization of human 
and rodent cell lines by [CONTACT_372375] -1001, a novel inhibitor of poly(ADP -ribose) polymerase. Cancer Lett. 
Mar 18 2004;205(2):155-160. 42. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and 
radiosensitization by [CONTACT_372376](ADP -ribose) polymerase- [ADDRESS_1277884]. Jan 7 2004;96(1):56-67. 
43. Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic 
parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. Oct 
1997;283(1):46-58. 44. Tan AR, Toppmeyer D, Stein MN, et al. Phase I trial of ABT- 888 (veliparib), (ABT -888), 
a poly(ADP -ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and 
cyclophosphamide in bre ast cancer and other solid tumors. ASCO Meeting Abstracts. June 9, 2011 
2011;29(15_suppl):3041. 45. LoRusso P, Ji JJ, Li J, et al. Phase I study of the safety, pharmacokinetics (PK), and 
pharmacodynamics (PD) of the poly(ADP -ribose) polymerase (PARP) inhibitor ABT -888 (veliparib) 
(ABT -888; V) in combination with irinotecan (CPT -11; Ir) in patients (pts) with advanced solid 
tumors. ASCO Meeting Abstracts. June 9, 2011 2011;29(15_suppl):3000.  
46. Chiarugi A. Poly(ADP -ribose) polymerase: killer or conspi[INVESTIGATOR_13521]? The 'suicide hypothesis' 
revisited. Trends Pharmacol Sci. Mar 2002;23(3):122-129. 
47. Virag L, Szab o C. The therapeutic potential of poly(ADP -ribose) polymerase inhibitors. 
Pharmacol Rev. Sep 2002;54(3):375-429. 
Alliance A091101  
 
Version Date: 08/11/2017  78 Update #07  48. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA 
base excision -repair with purified human proteins: interaction between DNA polymerase beta and 
the XRCC1 protein. EMBO J. Dec 2 1996;15(23):6662-6670. 
49. D'Atri S, Tentor i L, Lacal PM, et al. Involvement of the mismatch repair system in 
temozolomide-induced apoptosis. Mol Pharmacol. Aug 1998;54(2):334-341. 
50. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using 
a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in 
non small- cell lung cancer. J Natl Cancer Inst. Oct 3 2007;99(19):1455-1461. 
51. Lavin PT. An alternative model for the evaluation of antitumor activity. Cancer Clin Trials. 
Winter 1 981;4(4):451-457. 
52. Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck 
S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.  New response evaluation criteria in solid tumors:  revise d RECIST guideline (version 1.1).  Eur J Cancer 
45(2):  228-247, 2009. 
53. Herman, L.C., et al., Comparison of carboplatin–paclitaxel to docetaxel –cisplatin -5–
flurouracil induction chemotherapy followed by [CONTACT_910239]. Oral Oncology, (0). 
54. Airoldi, M., et al., Induction chemotherapy with carboplatin and taxol followed by 
[CONTACT_910240] + taxol in locally advanced nasopharyngeal 
carcinoma. Cancer Chemotherapy and Pharm acology, 2011. 67 (5): p. 1027-1034. 
55. Cmelak, A.J., et al., Phase II Trial of Chemoradiation for Organ Preservation in Resectable 
Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern 
Cooperative Oncology Group Study E2399. Journal of Clinical Oncology, 2007. 25(25): p. 3971-
3977. 
56. Machtay, M., et al., Organ Preservation Therapy Using Induction Plus Concurrent 
Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania 
Phase II Trial. Journal of Clinical Oncology, 2002. 20(19): p. 3964-3971. 
57. Salama, J.K., et al., Induction chemotherapy and concurrent chemoradiotherapy for 
locoregionally advanced head and neck cancer: a multi -institutional phase II trial investigating three 
radiotherapy dose levels. Annals of Oncology, 2008. 19 (10): p. 1787-1794. 
58. Vokes, E.E., et al., Weekly Carboplatin and Paclitaxel Followed by [CONTACT_910241], Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ -Preserving 
Therapy for Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2003. 21(2): p. 320-
326. 
Alliance A091101  
 
Version Date: 08/11/2017  79 Update #07  APPENDIX  A- PERFORMANCE STATUS CRITERIA  
 
ECOG Performance Status Scale  
Grade  Descriptions  
0 Normal activity.  Fully active, able to 
carry on all pre- disease performance 
without restriction.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able to 
carry out work of a light or sedentary 
nature ( e.g., light housework, office 
work).  
2 In bed <50% of the time.  Ambulatory 
and capable of all self -care, but unable 
to carry out any work activities.  Up 
and about more than 50% of waking 
hours.  
3 In bed >50% of the time.  Capable of 
only limited self -care, confined to bed 
or chair more than 50% of waking 
hours.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self -
care.  Totally confined to bed or chair.  
5 Dead.  
 
Alliance A091101  
 
Version Date: 08/11/2017  80 Update #07  APPENDIX  B - HEAD & NECK STAGING  
Edge, SB, ed. AJCC Cancer Staging Manual. 7th ed. [LOCATION_001], NY: Springer; 2010. 
 
PRIM ARY T UMOR (T) 
TX Primary tum or can not be assessed 
T0 No evid ence of primary tu mor 
Tis Carci noma in situ 
 
 
LIP and ORAL CA VITY  
 
TX Primary tum or can not be assessed 
T0 No evid ence of primary tu mor 
Tis Carci noma in situ 
T1 Tumor [ADDRESS_1277885] dime nsion 
T4a Mode rately advanced l ocal diseas e* 
 
(lip) Tumor i nvad es through cortic al bone,  infe rior alveolar  nerve, floor  of 
mouth, or skin of face (i.e., chin or nose) 
 
(oral  cavity)  Tumor invades adjacent struct ures only (e.g., through co rtical  bone 
[mandible or maxilla]  into deep [extrins ic] muscle of  tongue [geniogloss us, 
hyogloss us, p alatogloss us, and styloglossus],  maxillary  sinus, skin of face)  
T4b Very adva nced dise ase 
 
Tumor  inva des  masticator  space,  pterygoid  plates  or  skull  base and/or  encases  
internal carotid art ery 
*Note: Supe rficial erosi on alone of bone/ tooth socket by [CONTACT_910242] a 
tumor as T4.  
NAS AL CAVITY and PARANASAL  SINUSES  Maxilla ry Sinus 
T1 Tumor limit ed to maxillary sinus m ucosa  with no eros ion or de struc tion of bone 
T2 Tumor causing bone erosion or de struction including extension into the hard palate 
and/or middle nasal  meatus, ex cept exten sion to posterior wall  of maxill ary sinus  and 
pterygoid  plates  
T3 Tumor invades any of the  following: bone of the posterior  wall  of maxillary sinus, 
subcutaneous tissu es, floor or me dial wall  of orbit, pterygoid fo ssa, ethmoid sinuses 
T4a Mode rately advanced l ocal disease 
 
Tumor invade s anter ior orb ital conten ts, skin of ch eek, pterygoid pla tes, 
infratem poral fossa, cri briform plat e, sph enoid o r frontal s inuses 
T4b Very adva nced local d isease 
 
Tumor invade s any of the followi ng: orbi tal apex, dura, brain, middle cran ial foss a, 
cranial nerv es othe r than maxill ary division of trigeminal nerve (V2), naso pharynx or 
clivus  
Alliance A091101  
 
Version Date: 08/11/2017  81 Update #07  Nasal Ca vity and Ethmoid Sinus  
T1 Tumor re stricted to any one subs ite, wit h or with out bony invasi on 
T2 Tumor invading two subs ites in  a single region or ext ending to involv e an adj acent 
region within the nasoethmoidal complex, with or without bony invasion 
T3 Tumor extends to invade the medial  wall or floor of the orbit, maxillary  sinus, pal ate, 
or cribriform pla te 
T4a Mode rately advanced l ocal disease 
 
Tumor invade s any of the followi ng: ant erior orbital c ontents, skin of nose o r cheek, 
minimal extensio n to anteri or cran ial fossa, pterygoid  plates, sphenoi d or frontal 
sinuses 
T4b Very adva nced local d isease 
 
Tumor invades any of the followi ng: orbi tal apex, dura, brain, middle cran ial foss a, 
cranial nerv es othe r than V2, nasopharynx, or cl ivus 
PHARYNX Nas ophar ynx 
T1 Tumor confi ned to the nasopharynx, or tumor exte nds to oropharynx and/or na sal 
cavity  with 
out parapha ryngeal  extension* 
T2 Tumor with parapharynge al extensi on* 
T3 Tumor involv es bony str uctures  of skull base and/ or paranasal si nuses 
T4 Tumor with intracran ial extens ion and/or  involvement of cranial nerves,  
hypopharynx, orbit,  or with extens ion to the infratemp oral fossa/mast icator  space 
 
*Note: Par apharyn geal extension denot es po sterolat eral infiltrati on of tumor. 
 
Oroph arynx 
T1 Tumor [ADDRESS_1277886]  
palate,  or mandibl e* 
T4b Very adva nced local d isease 
 
Tumor invades lateral  ptery goid musc le, pterygo id plates, lateral  nasopharynx, or 
skull  base  or encases carotid artery  
 
*Note: Mucosal  extension to lingual surface of epi[INVESTIGATOR_910198] o rs of the base of the 
tongue and vallecu la doe s not c onstit ute invasion  of larynx. 
 
Hypopha rynx  
T1 Tumor limit ed to one su bsite of hypopharynx and/or [ADDRESS_1277887] diamet er without 
Alliance A091101  
 
Version Date: 08/11/2017  82 Update #[ADDRESS_1277888] dimensi on or with fixation  of 
hemil arynx or extensi on to es ophagus 
T4a Mode rately advanced l ocal disease 
 
Tumor  invades  thyroid/ cricoid  cartilage,  hyoid  bone,  thyroid  gland,  esoph agus  
or  centr al compartment s oft tissue.* 
T4b Very adva nced local d isease 
 
Tumor invade s prev ertebral fascia, enca ses carotid artery, or involves medi astinal 
structures 
 
*Note: Central compartm ent soft tissue include s pre laryngeal  strap muscle s and  subcutane ous fat.  
LARY NX 
 
Supraglottis  
T1 Tumor limit ed to one su bsite of su praglo ttis with nor mal vocal cord  mobility  
T2 Tumor i nvades mucosa  of more  than  one adjacent subsite  of supraglottis  or gl ottis 
or region outsi de the supra glottis  (e.g., mucosa of base of tongue, vall ecula, medial 
wall of  pyriform sinu s) without fixation of the larynx  
T3 Tumor limited to larynx with vo cal cord fi xation and/or invad es any of the  following:  
postcricoid area, pre-epi[INVESTIGATOR_743987], paraglottic spac e, and/or inner cortex of thyroid 
cartilage  
T4a Mode rately advanced l ocal disease 
 
Tumor inv ades thr ough the thyroid cart ilage  and/or invad es tiss ues beyond the larynx  
(e.g., trac hea, soft tissues of the neck  including deep extrinsic musc le of the  tongue, 
strap  muscl es, thyroid, or esophagus)  
T4b Very adva nced local d isease 
 
Tumor inv ades prev ertebral space, encase s carotid artery, or inva des med iastinal 
structures 
 
Glottis  
T1 Tumor limited  to the vocal  cord(s) [may  involve  anter ior or post erior commi ssure] 
with normal mobility  
T1a Tumor  limit ed to one vocal cord 
T1b Tumor involves both vocal  cords 
T2 Tumor extends to supragl ottis and/or  subglottis, and /or with impa ired vocal cord 
mobility  
T3 Tumor limited to the l arynx with vocal cord  fixati on, and/or invasion of 
paraglottic  space, and/or i nner cortex of the thyroid c artilage 
T4a Mode rately advanced l ocal disease 
 
Tumor invade s through the outer cortex of  the thyroi d cartil age and /or invades tissues 
beyond the  larynx  (e.g., trachea, soft  tissues of neck  including deep extrins ic muscle 
of the tongue , strap m uscles, thyroid, or esophagus)  
T4b Very adva nced local d isease 
 
Alliance A091101  
 
Version Date: 08/11/2017  83 Update #[ADDRESS_1277889](s)  with n ormal or impa ired mobility   
 
T3 Tumor limited  to larynx with  vocal cord  fixation   
T4a Mode rately advanced l ocal disease   
  
Tumor invade s crico id or t hyroid ca rtilage and /or inv ades tiss ues beyond the larynx  
(e.g., trach ea, soft tissu es of neck incl uding de ep extrins ic muscl es of the tongue, 
strap muscle s, thyroid, or esophagus)   
 
T4b Very adva nced local d isease 
 
Tumor invade s prev ertebral space, encase s carotid artery, or invades med iastinal 
structures.    
REGI ONAL  LYMPH N ODES (N) Excl uding Nasophary nx 
 
NX Regional lymph nodes cannot be ass essed 
N0 No regional lymph node m etastas is 
N1 Metastasis in  a sing le ipsilateral no de, [ADDRESS_1277890] dime nsion 
 
REGI ONAL  LYMPH N ODES (N) Nasophar ynx 
NX Regional lymph nodes cannot be ass essed 
N0 No regional lymph node m etastas is 
N1 Unilat eral m etastasis in lymph node(s),  [ADDRESS_1277891] dime nsion 
Alliance A091101  
 
Version Date: 08/11/2017  84 Update #[ADDRESS_1277892] dime nsion 
 
DISTANT M ETASTASIS (M)  
 
M0 No d istant metast asis 
M1 Distant metastasis   
 
 
 
STAGE GROUPI[INVESTIGATOR_1645], Exc luding Nasopha rynx STAGE GROUPI[INVESTIGATOR_910199] 0 Tis, N 0, M 0 Stage 0 Tis, N0, M0 
Stage  I T1, N0, M 0 Stage  I T1, N0, M0  
Stage  II T2, N0, M0 Stage  II T2, N0, M0  
Stage III  T3, N0, M0  
T1-3, N1,  M0 
Stage  IVA  T4a, N0-1, M0 
Any T, N2, M0 
Stage  IVB  T4b, Any  N, MO Any  T, N3, M0  
Stage III  T1-T3, N1, M0 
T3, N0, M0  
Stage IV A  T4a, N0-2, M0 
T1-3, N2,  MO 
Stage  IVB  Any T, N3, M0 
T4b, Any  N, M0 
Stage  IVC  Any T, Any  N, M1 Stage  IVC  Any T, Any  N, 
M1 
 
  
Alliance A091101  
 
Version Date: 08/11/2017  85 Update #07  APPENDIX  C - ABT -888  PATIENT  MEDICATION  CALENDAR  
Pi[INVESTIGATOR_910200] -888: 
Carboplatin -Paclitaxel Induction chemotherapy and ABT- 888 (Veliparib) – a Phase 1/Randomized 
Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head 
and Neck  
 
Number of Pi[INVESTIGATOR_69689]:____________  Pi[INVESTIGATOR_593536](s) returned:  Circle Yes or No  
Total Daily Dose:________________    
Number of Pi[INVESTIGATOR_114452]:_____________ (To be Completed by [INVESTIGATOR_41886])  
    
PLEASE FILL OUT AND BRING THIS SHEET TO ALL VISITS.  
 
SPECIAL INSTRUCTIONS  
1. ABT -888 should be taken orally, twice a day, on days 1 through 7 of each induction 
chemotherapy cycle  
CYCLE #: _______   
DAY  Medication  DATE  TIME /notes  # of pi[INVESTIGATOR_3353]/mg  
taken  
Example  ABT -888 07/01/2012  9:00 AM 9:00 PM   
1 ABT -888        
2 ABT -888        
3 ABT -888        
4 ABT -888        
5 ABT -888        
6 ABT -888        
7 ABT -888        
8         
9         
10         
11         
12         
13         
14         
15         
16         
17         
18         
19         
20         
21         
  
Patient Signature: _________________________________________Date:__________  
   Consenting Professional/Research RN Signature: ______________Date:__________  
 Comments:_____________________________________________________________  
 